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Summary 
In African trypanosomes, the control of transcription initiation by RNA pol II is absent 
at the level of individual mRNAs. Nevertheless, gene expression changes 
dramatically during life cycle transitions in response to the changing host 
environments. In the bloodstream of the mammalian host, Trypanosoma brucei exist 
as proliferative long slender forms or as a non-dividing stumpy forms; the latter 
differentiate to procyclic forms in the midgut of the tsetse fly. Differential gene 
expression between life cycle stages is achieved through regulation of mRNA 
degradation and translation, and mainly relies on RNA binding proteins. The work 
focuses on the RNA binding protein RBP10. RBP10 is a bloodstream form specific 
cytoplasmic protein with a single RRM domain. Depletion of RBP10 in bloodstream 
forms or forced expression in the procyclic forms is lethal due to mis-regulation of 
developmentally expressed mRNAs. Bloodstream forms cells depleted of RBP10 
differentiate to procyclic forms after transfer into procyclic growth media and 
incubation at 27oC; within three days, >80% of the cells express GPEET procyclin, 
and reposition their kinetoplast. Conversely, expression of RBP10 in procyclic cells 
for two days converts the cells to bloodstream forms. In such cells, eight VSG 
transcripts, including three with metacyclic promoters, were strongly up regulated, 
and ~16% of the cells had acquired a VSG surface coat. More importantly, a subset 
of the cells survived after transfer into bloodstream form growth media and 
incubation at 37oC, resulting in proliferating cells in about ten days.  
Tethering of RBP10 to a reporter mRNA inhibits translation and promotes mRNA 
degradation. RBP10 from bloodstream forms co-precipitated many procyclic specific 
mRNAs that are normally unstable in bloodstream forms. Indeed, 39% of the 
mRNAs up regulated after RBP10 depletion were bound by it; these included the 
transcript encoding procyclic surface coat EP procyclin, several enzymes needed 
for procyclic energy metabolism, regulatory proteins ZC3H21, ZC3H20, two kinases 
and a phosphatase. The UA(U)6 motif was found to be highly enriched in the 3' UTR 
of RBP10 mRNA targets. Binding of RBP10 to EP 3’ UTR was lost when the UA(U)6 
motif was deleted from a reporter mRNA, and the motif was also necessary for its 
regulation by RBP10. In bloodstream forms RBP10 target mRNAs are likely to be 
blocked from translation hence degraded; this is important for survival. Perturbation 
of RBP10 expression therefore triggers a regulatory cascade that is sufficient to 
modulate T. brucei developmental capacity. 
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Zusammenfassung 
Bei afrikanischen Trypanosomen gibt es keine Kontrolle der Transkriptionsinitiation 
durch RNA Pol II auf der Ebene einzelner mRNAs. Nichtsdestotrotz verändert sich 
die Genexpression während der Übergänge im Lebenszyklus als Reaktion auf die 
unterschiedlichen Wirts-Umgebungen dramatisch. Im Blutstrom des Säugerwirts 
existiert Trypanosoma brucei als proliferative lange Form (slender) oder als sich 
nicht teilende gedrungene Form (stumpy); letztere differenziert im Mitteldarm der 
Tsetsefliege zur prozyklischen Form. Unterschiede der Genexpression in den 
verschiedenen Lebenszyklusstadien werden durch die Regulierung der Degradation 
und Translation von mRNAs erreicht und sind vor allem auf RNA-bindende Proteine 
zurückzuführen. Diese Arbeit konzentriert sich auf das RNA-bindende Protein 
RBP10. RBP10 ist ein zytoplasmatisches Protein, das spezifisch für die Blutstrom-
Form ist und eine einzelne RRM-Domäne besitzt. Die Depletion von RBP10 in der 
Blutstrom-Form oder die erzwungene Expression in der prozyklischen Form sind 
letal, da mRNAs, die entwicklungsbedingt exprimiert werden, fehlreguliert werden. 
Die Depletion von RBP10 in der Blutstrom-Form führt nach dem Transfer dieser 
Zellen in prozyklisches Medium und Inkubation bei 27°C zur Differenzierung in die 
prozyklische Form. Innerhalb von drei Tagen exprimieren >80% dieser Zellen das 
Prozyklin GPEET und re-positionieren den Kinetoplasten. Wird RBP10 dagegen 
zwei Tage in prozyklischen Zellen exprimiert, führt dies zur Bildung der Blutstrom-
Form. In diesen Zellen sind acht VSG-Transkripte stark hoch-reguliert, darunter drei 
mit metazyklischen Promotoren, und ~16% der Zellen haben eine VSG-
Oberflächenschicht. Darüber hinaus überlebte ein Bruchteil der Zellen den Transfer 
in Blutstrom-Form Wachstumsmedium und Inkubation bei 37°C. Dies führte nach 
etwa 10 Tagen zu teilungsaktiven Zellen.  
Die Bindung von RBP10 an eine Reporter-mRNA inhibiert deren Translation und 
fördert deren Degradation. Die Präzipitation von RBP10 in der Blutstrom-Form hat 
viele mRNAs mitausgefällt, die spezifisch für die prozyklische Form sind und 
normalerweise in der Blutstrom-Form nicht stabil sind. Tatsächlich waren 39% der 
mRNAs, die nach Depletion von RBP10 hoch-reguliert waren, an RBP10 gebunden; 
dies umfasste das Transkript, welches das prozyklische Oberflächenprotein EP 
Prozyklin kodiert, sowie einige Enzyme, die für den prozyklischen Metabolismus 
benötigt werden, die regulatorischen Proteine ZC3H21 und ZC3H20, zwei Kinasen 
und eine Phosphatase. In den 3’UTRs der mRNAs, die an RBP10 binden, wurde 
vermehrt das Motiv UA(U)6 gefunden. Die Entfernung des UA(U)6 Motives in der EP 
3’UTR einer Reporter-mRNA führte zu einem Verlust der Interaktion mit RPB10. 
Außerdem ist dieses Motiv für die Regulation der mRNA durch RBP10 nötig. In der 
Blutstrom-Form wird die Translation der Ziel-mRNAs von RBP10 vermutlich blockiert 
und diese daher abgebaut, was für das Überleben wichtig ist. Eine Störung der 
Expression von RBP10 löst daher eine regulatorische Kaskade aus, die ausreicht, 
um das Entwicklungspotential von T. brucei zu verändern. 
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1 Introduction 
1.1 Background  
Trypanosomes are protists that belong to the class Kinetoplastida. The class 
comprises of flagellated unicellular organisms that infect humans, animals and 
plants; many Kinetoplastids are transmitted by arthropods. Several Trypanosoma 
brucei subspecies cause a poverty-related vector-borne infectious disease in either 
humans (sleeping sickness) or animals (nagana in cattle) in sub-saharan Africa. 
Close relatives of trypanosomes include Leishmania spp. (causes various cutaneous 
and visceral leishmaniasis) and Trypanosoma cruzi (causes Chagas disease).  
Trypanosoma brucei was first detected more than a century ago as the parasitic 
agent responsible for what was then called ‘tsetse fly disease’ or nagana in African 
cattle [1]. Later on trypanosomes were linked to a human disease called sleeping 
sickness after detection of the parasite in patients blood [2] and cerebral spinal fluids 
[3]. Follow-up studies revealed that T. brucei is cyclically transmitted between 
mammalian hosts by the tsetse fly [4]. Currently, Human African Trypanosomiasis 
(HAT) or sleeping sickness affects 36 countries in sub-Saharan Africa where the 
tsetse fly is found (http://www.who.int/mediacentre/factsheets/fs259/en/). 
 
1.2 Diseases caused by T. brucei  
Two T. brucei subspecies, T. b. gambiense and T. b. rhodesiense, infect both 
humans and animals. T. b. gambiense is mainly present in West and Central Africa, 
and usually causes a chronic form of infection; pigs have been identified as a 
potential reservoir but the epidemiological role for the animal reservoir is not well 
understood. In contrast, T. b. rhodesiense is mainly zoonotic and only occasionally 
infects humans. It is found in Eastern and Southern Africa, where it is known to 
cause an acute form of HAT. The gambiense form of HAT accounts for more than 
95% of the reported cases [5]. In 2009 the reported HAT cases were <10,000 for the 
first time in 50 years, and in 2015 only 2804 cases were recorded 
(http://www.who.int/mediacentre/factsheets/fs259/en/). This is attributed to the 
continuous active surveillance for HAT, vector control and treatment for HAT cases 
[6]. Such efforts need to be well sustained in order to achieve the WHO’s target to 
eliminate HAT as a public health burden by 2030. For T. b. rhodesiense, a major 
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challenge is the parasite reservoir in wild animals which acts as a source for new 
human infection. 
 
HAT occurs in two clinical stages [6-8]. In the early/first stage, parasites are found 
mainly in the bloodstream and the lymphatic system, also known as the hemo-
lymphatic stage. The late/second stage of the disease begins when the parasites 
cross the blood- brain barrier and invade the central nervous system. Early stage 
HAT patients develop unspecific clinical signs including intermittent fever, headache, 
pruritus, joint pains, weakness and weight loss [9, 10]. The onset of the late stage is 
characterised by the appearance of neuro-psychiatric symptoms including mental 
changes and sleep disturbances [6]. If left untreated at this point, the disease leads 
to coma, multiple organ failure and eventually death. 
Unfortunately, vaccination is not an option for HAT treatment due to the antigenic 
variation phenomenon in trypanosomes; a process where bloodstream form 
trypanosomes escape host immune response by switching their variant surface 
glycoproteins (VSGs) that coat the outer membrane. The choice of drugs for treating 
HAT depends on the stage of the disease and species of the parasite. Early stage T. 
b. gambiense HAT is treated using pentamidine administered by intramuscular 
injections once daily for 7 days [11] while the late stage is treated with nifurtimox-
eflornithine combination therapy (NECT) [12]; nifurtimox is administered orally three 
times a day for ten days in combination with intravenous eflornithine given every 12h 
for 12 days. For T. b. rhodesiense HAT, the early stage is treated with suramin 
administered by slow intravenous infusions every 3-7 days for four weeks [13]; the 
late stage is treated using melarsoprol (an arsenical drug) administered 
intravenously in a 10-day regimen [11]. Melarsoprol treatment produces a reactive 
encephalopathy in ~10% of the patients, and half of those cases are fatal [11]. 
All the current anti-trypanosomal agents are considered undesirable due to low 
efficacy, difficulty in administration, dangerous side effects, and emerging resistance. 
However, there is hope for new drugs against HAT with two compounds fexinidazole 
and benzoxaborole (SCYX-7158), currently in advanced stages of clinical trials 
under direction by the Drugs for Neglected Diseases initiative (DNDi) [11, 14]. 
The major trypanosome species responsible for Animal African trypanosomiasis 
(AAT) are T. congolense and T. vivax [15, 16]. AAT is recognized as a major 
economic constraint especially in the rural areas where it is estimated to cause more 
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than $1300 million annual losses to livestock producers and consumers [17]. Other 
minor pathogens for AAT include T. godfreyi, T. simae, and T. b. brucei. 
Transmission mainly involves the tsetse fly but mechanical transmission by biting 
flies has been reported for some of the species under laboratory conditions [18-20]. 
In most primates including humans, trypanosome species causing AAT get killed by 
trypanolytic factors (TLFs) present in the serum [21]. T. b. gambiense and T. b. 
rhodesiense which infect both humans and animals developed mechanisms to avoid 
lysis by the human serum factors. T. b. rhodesiense express a serum resistance 
associated gene, SRA, which binds TLF-1 protecting the parasite from lysis [22] 
while T. b. gambiense uses a multifactorial strategy involving expression of specific 
glycoprotein (TgsGP) that prevents the parasite killing effect of apolipoprotein L1 
APOL1 (part of the TLFs), and a mutation that inactivate haptoglobin-hemoglobin 
receptor resulting to decreased TLF-1 uptake [23, 24]. 
 
As early diverging eukaryotes, trypanosomes share features common in most 
eukaryotes, but also they have very unusual features which makes them interesting 
model organisms. For example they have a single mitochondrion and the 
mitochondrial genome is organized into a disk like structure called the kinetoplast 
[25]. The mitochondrion respiratory activity is also developmentally regulated; in 
bloodstream stage, the size and activity of the mitochondrion is significantly reduced 
because the parasite depends on glycolysis for energy generation. In contrast, a fully 
functional and more elaborate mitochondrion exists in the insect stage procyclic 
forms which mainly depend on oxidative phosphorylation of amino acids for energy 
generation. Another peculiar characteristic is separation of various metabolic 
enzymes including most glycolytic enzymes into a peroxisome-like organelle known 
as the glycosome [26, 27], and the use of RNA polymerase I to transcribe genes 
encoding the major surface proteins, VSG and procyclins [28]. 
 
1.3 T. brucei cell structure  
Trypanosomes have a single flagellum with a canonical axoneme structure plus an 
associated paraflagellar rod [29]. They swim with the flagellum tip leading. Apart 
from cell motility, the T. brucei flagellum is involved in cytokinesis and might function 
as a sensory organelle [30]. The flagellum is attached on the entire cell body (apart 
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from the distal tip) using a filament and a set of four specialized microtubules that 
form a structure known as the flagellum attachment zone (FAZ) [31]. Trypanosomes 
have several other organelles typical of eukaryotic cells such as the nucleus with 
nuclear membrane, Golgi apparatus, endoplasmic reticulum network, endosomes 
and lysosomes. The single mitochondrial DNA is composed of concatenated maxi 
and mini circles. The maxi-circles contain genes encoding mitochondrion proteins; 
some of their pre-mRNAs undergoe editing using guide RNAs (transcribed from both 
maxi and mini circles) as templates to generate mature mRNAs [32, 33]. The 
kinetoplast is physically attached to the basal body of the flagellum and this is 
important for segregation during cell division [34]. A trypanosome cell where the 
kinetoplast is placed posterior to the nucleus is known as the trypomastigote (see 
Figure 1.3), if the kinetoplast is placed anterior of the nucleus the cell is referred to 
as an epimastigote. A sub-pellicular microtubules corset helps to define the cell 
shape. The cytoskeleton network is enclosed by the plasma membrane and is only 
interrupted where the flagellum exits the cell body to form the flagellar pocket, which 
is the only site of endo and exocytosis [35]. 
 
Figure 1.3 Ultrastructure of a T.brucei bloodstream form trypomastigote. Taken from 
[36]. 
 
1.4 T. brucei life cycle  
The T. brucei life cycle is digenetic. It involves a vertebrate host and a blood feeding 
insect, the tsetse fly (Figure 1.4). The environments in the two hosts differ in 
temperature, nutritional levels, pH and immune response. To survive in such variable 
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environments, trypanosomes have to sense and respond accordingly. Within various 
tsetse fly tissues more than 10 distinct morphological forms have been observed 
[37]. In the mammalian host, pleomorphic strains exist as proliferative long slender 
forms, which transform to growth arrested stumpy forms at peak parasitaemia. T. 
brucei transmission is initiated when a tsetse fly feeds on an infected mammalian 
host. The hostile environment in the midgut kills the long slender bloodstream form 
while the stumpy forms differentiate into proliferative procyclic forms after 2-5 days. 
This entail cell enlargement, kinetoplast repositioning, increased mitochondrion 
respiratory activity and the replacement of the variant surface glycoprotein (VSG) 
coat with a less dense coat composed of procyclins; GPEET procyclin is present 
only in early procyclic forms, the late procyclic forms express EP procyclin instead 
[38-40]. After proliferation, migration to the foregut is accompanied by the 
appearance of elongated mesocyclic forms, and soon after long epimastigotes in the 
proventriculus [41]. The long epimastigotes undergo asymmetric division giving rise 
to both long and short epimastigotes [41], usually covered by a surface coat protein 
called BARP and with the kinetoplast positioned anterior to the nucleus [42]. The 
short epimastigote goes on to colonize the salivary gland [43, 44] and it is believed 
the long epimastigote helps to deliver the short epimastigotes (poor swimmers) to 
the salivary gland. Outgrowth of the flagellar membrane enables the short 
epimastigotes to get attached to the salivary gland epithelium while they differentiate 
to pre-metacyclics [30, 45]. Finally after a cell cycle arrest, nascent metacyclic forms 
covered with the VSG coat get released into the saliva ready to be transferred into 
the next mammalian host.  
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Figure 1.4 A simplified illustration showing the lifecycle of T. b. brucei. Image 
adopted from http://www.yourgenome.org/facts/what-is-african-sleeping-sickness.  
 
Trypanosomes live extracellularly in the blood and tissue fluids of a mammalian host 
or in several tissues of the tsetse fly. As a result they get exposed to various immune 
defence systems present in the host. In the vertebrate host, the trypanosome cell 
surface is covered with a dense (15 nm thick) homogeneous coat [46] made up of 
107 molecules of a single variant surface glycoprotein (VSG) which is linked to the 
cell membrane via a glycosylphosphatidylinositol (GPI) anchor [47]. The VSG coat is 
highly immunogenic but trypanosomes escape adaptive immunity through periodic 
switching to a different VSG; a phenomenon known as antigenic variation [48]. This 
occurs in one out of a thousand cells [49]. Trypanosome infection is therefore 
characterized by waves of parasitaemia where trypanosome populations are 
periodically eliminated but parasites that switch VSG survive and re-establish an 
infection. Apart from the variable function, the dense and thick VSG coat protects the 
less variable or invariant surface proteins such as the nutrient receptors from 
immune effectors [50]. Since the trypanosome virulence depends on the VSGs, the 
parasite has dedicated about 30% of its genome to archiving about 2000 VSGs 
genes and gene fragments; most of them are pseudogenes or have frame shift 
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mutations. However, productive VSGs are generated via mosaic formation, hence 
the VSG repertoire is almost unlimited [50-52].  
Surface coat exchange during life stage transitions is used as a hallmark for 
trypanosome life cycle progression, but is only one of the many changes associated 
with the extensive transcriptome and proteome remodelling necessary for survival in 
and adaptation to different host environments. It is often initiated by environmental 
cues such as, pH, nutrient levels, temperature and chemical triggers [53, 54].  
 
1.5 Gene regulation in trypanosomes 
1.5.1  Transcription  
Unlike other eukaryotes, trypanosomatids have a peculiar mechanism to transcribe 
and process mRNAs [55]. Transcription in trypanosomatids is polycistronic. In the 
case of T. brucei, genes present in the eleven megabase homologous chromosome 
pairs (which contains most RNA and protein coding genes) are organized into long 
unidirectional clusters of tens to hundreds of genes. Introns and individual promoters 
are absent for almost all of the protein coding genes [56]. Transcription initiation by 
RNA polymerase II is bidirectional and appears to be regulated by histone variants 
and modifications rather than transcription factors [57, 58]. The only exception is the 
splice leader (SL) gene cluster where a specific promoter and specific transcriptional 
factors are required [59-61].  
Genes present in a single transcription unit are mostly functionally unrelated and it is 
assumed that transcription by RNA polymerase II happens at a uniform rate. 
However, large differences in mRNA and protein levels are observed between genes 
belonging to the same polycistronic transcription unit, and between developmental 
stages [62]. This is due to post-transcriptional regulatory mechanisms operating at 
the levels of pre-mRNA processing, mRNA transport, localization, stability and 
translation. Monocistronic mature mRNAs are generated from the long pre-mRNA 
through trans-splicing and coupled polyadenylation of the upstream transcript [63]. 
Trans splicing entails addition of a 39 nucleotide splice leader sequence to the 5’ of 
each mRNA. This provides the mRNA cap (cap 4) plus elements needed to improve 
mRNA stability and translation. Cis-splicing is rare with only two trypanosome 
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transcripts having been reported to be cis-spliced [64, 65]. Transcripts required in 
high amounts exist as multi-copy genes in the genome. The highly expressed genes 
encoding VSG and procyclins are transcribed by pol I which is ten times more active 
than pol II [63]. 
 
1.5.2 Post transcriptional regulation in trypanosomatids  
After maturation in the nucleus, the mRNA is bound by RNA binding proteins (RBPs) 
which help with the export from the nucleus to the cytoplasm. Here the fate of the 
mRNA is determined by additional RBPs that get recruited mostly via cis-acting 
elements present in the 3’ untranslated regions (UTRs), or by protein-protein 
interactions to form a messenger ribonucleoprotein (mRNP) complex. Translating 
mRNA associates with the cap binding protein eIF4E and interacts with the scaffold 
protein eIF4G that circularizes the mRNP by interacting with poly A binding protein 
PABP1 bound to the poly A tail at the 3’ UTR of the mRNA. Additional translation 
initiation factors help to recruit the 40S ribosomal subunit to form the translation pre-
initiation complex that begins to scan for the start codon. Some T. brucei translation 
factors are highly expanded with genes encoding six eIF4E and five eIF4G variants 
being present in the genome [66]. TbeIF4E sequences are highly diverged from 
those in other eukaryotes, perhaps to accommodate the hyper-methylated cap 4 
structure. eIF4E-4 and its partner eIF4G-3 are considered responsible for the global 
translation; it is not known whether translation initiation is regulated by having 
different eIF4E and eIF4G combinations. On the other hand, mRNAs that are not 
translated can be stored in membrane free granules/aggregates in association with 
different protein components; examples of such aggregates are p-bodies and stress 
granules [67]. P-bodies are thought to be the sites of mRNA degradation usually 
containing the decapping enzymes, the enhancer of decapping RNA helicase DHH1 
and the 5’-3’ exoribonuclease XRN1. The stress granules are aggregates of mRNPs 
stalled in the process of translation initiation, normally induced by different types of 
stress [67]. Both types of granules are present in trypanosomes [68, 69]; a recent 
study identified many RNA metabolism-related proteins as new components of 
starvation granules in T. brucei procycic forms [70]. 
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In yeast and mammalian cells, mRNA translation and degradation are interlinked and 
considered as competing processes [67]. mRNA degradation is initiated by 
shortening of the poly A tail by the CCR4/CAF1/NOT complex [71], then the 
exosome complex degrades the mRNA from 3’-5’ direction [72, 73]. After decapping, 
XRN1 degrades the mRNA from the 5’-3’ direction [67, 74]. So far the T. brucei 
decapping protein is still unknown but trypanosome cell extracts are known to 
contain decapping activity [75]. Unlike some other eukaryotes, kinetoplastids lack a 
CCR4 homolog, the rest of the NOT complex subunits are present [76]. CAF1 is the 
major deadenylase in T. brucei with CAF1/NOT complex being required for global 
mRNA degradation [77]; another deadenylase PAN2/PAN3 seems to be important in 
the degradation of some unstable mRNAs [78, 79]. mRNA degradation is regulated 
via sequence specific RBPs that interact with proteins of the degradation machinery 
[80, 81]. In T. brucei, such RBPs that interact with the degradation machinery have 
yet to be discovered. In a yeast two hybrid assay, T. brucei CAF1 was shown to 
interact with the zinc finger proteins ZC3H15 and ZC3H5 and the RRM-containing 
proteins DRBD5 and RBP31 [82], whether this is true in trypanosomes is yet to be 
determined. Moreover, a recent screen identified numerous novel proteins that lack 
classical RNA binding domains (RBDs) but associated with mRNAs in bloodstream 
form trypanosomes [82], some of the candidates were previously shown to increase 
or decrease expression of a reporter mRNA when bound on the 3’ UTR [83]; for 
most of them the mode of action and their biological functions are unknown. Follow 
up studies on those that decreased reporter mRNA might provide hints on how the 
degradation machinery gets recruited. 
To date several RNA binding protein (RBP) families have been studied in T. brucei, 
these mostly include proteins containing conserved RNA binding domains such as 
RNA recognition motifs (RRM), PUF, CCCH-type zinc finger and ALBA domains [55, 
84]. Similar to other organisms, RBPs with RRM domains are the most common in T. 
brucei; there are around 70. They include several RBPs conserved in other 
eukaryotes such as PABP1 and HnRNPH, while many others are unique to 
trypanosomatids [85, 86]. The RRM domain binds specific sequences on a single 
stranded RNA, but can also interact with DNA as well as other proteins. About half of 
the proteins containing RRM domain are required for T. brucei growth in at least one 
life-cycle stage [87]. However, only a few have been characterized. For example 
UBP1 and UBP2 whose mRNA targets are not known yet [88], RBP42 which binds 
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transcripts encoding energy metabolism proteins [89], HnRNPF/H which is 
expressed in the nucleus and cytoplasm, and can influence both mRNA stability and 
splicing [90]; finally, RBP10 [91] and RBP6 [92] are both implicated in differentiation 
regulation (will be described later). 
T. brucei has about 40 RBPs with CX8CX5CX3H zinc finger domains. ZFP1, ZFP2 
and ZFP3 are involved in differentiation from bloodstream to procyclic forms [93-95]. 
ZC3H20 is required for growth in procyclic forms; two procyclic specific mRNAs are 
bound and stabilized by ZC3H20 [96]. ZC3H11 is only essential in bloodstream form. 
In the procyclic forms ZC3H11 is required for heat shock response; it acts by 
stabilizing mRNAs encoding chaperone proteins through binding UAU motif present 
in the 3’ UTRs [97], and interaction with MKT1 and PBP1 which then recruits PABP 
[98].  
PUF (Pumilio and FBP) proteins are known to regulate mRNA stability and 
translation in other organisms. T. brucei has 11 PUF proteins. PUF9 stabilizes a 
small number of transcripts important in cell cycle control; a UUGUACC motif is 
required for PUF9 mediated regulation [99]. PUF7 and PUF10 are localized in the 
nucleolus. PUF7 interacts with nuclear cyclophilin 1, and has effect on rRNA 
maturation in procyclic forms [100]. NRG1, another nucleolar protein, interacts with 
PUF7 and PUF10 and the three proteins are implicated in the regulation of the 
mRNA that encodes GPEET procyclin surface protein [101].  
There are four T. brucei proteins with an ALBA (acetylation lowers binding affinity) 
domain, which can bind both DNA and RNA. All TbALBA proteins are present in the 
cytoplasm, but upon nutritional stress they relocate to stress granules [102, 103]. 
ALBA1/2 recognizes regulatory elements present in the GPEET procyclin mRNA, 
and can form complexes with ALBA3 and ALBA4. ALBA3 interacts with eIF4E4 and 
both ALBA2 and 3 partially co-migrate with polysomes [103]. This, taken together 
with the stress granule relocation indicates involvement in translation control. 
ALBA3/4 may be required for trypanosome differentiation regulation in the tsetse fly 
[102]. However, ALBA protein target mRNAs and their mode of action remain to be 
determined.  
1.6 Control of trypanosome differentiation 
T. brucei differentiation is triggered by external stimuli present in the different host 
environments. In other eukaryotes, the ultimate target of the signal transduction 
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pathways is usually a transcription factor which function to regulate specific gene 
expression. In case of T. brucei and other trypanosomatids, this is not possible since 
transcription control is absent [104]. Currently, studies investigating the molecular 
mechanisms regulating T. brucei differentiation are limited to the transition from long 
slender bloodstream to procyclic forms; which until very recently was the only one 
available. Some of the signaling pathways that are known or speculated to operate 
during bloodstream to procyclic life stage transitions can be classified into two 
phases. 
1.6.1 Bloodstream to stumpy forms transition 
Transition from bloodstream to stumpy forms is irreversible [105]. It involves well-
coordinated developmental programs characterized by cell cycle arrest and profound 
changes in cellular morphology and metabolism [53, 54]. In the mammalian host a 
parasite-specific signal acts as trigger for stumpy cells formation; it is commonly 
referred to as stumpy induction factor (SIF). So far the SIF molecule (or mixture of 
molecules) still remains to be identified. It is known that SIF gets released by 
proliferating long slender bloodstream forms at peak parasitaemia (>108 cells/ml) 
and acts in a mechanism similar to quorum sensing in microbial communities [106, 
107] Once SIF reaches a critical threshold, it triggers long slender cells to 
differentiate to cell-cycle arrested stumpy forms (adapted for survival in tsetse fly). 
How the parasite perceives SIF is yet to be determined since the identity of SIF is 
unknown. The possibility that cAMP signaling pathways are involved in SIF signal 
transduction has been widely investigated in T. brucei [106, 108, 109]. This was 
based on the reports that cAMP levels change during bloodstream to stumpy form 
differentiation [110]. It turned out the parasite do not recognise cAMP directly but 
rather the products of cAMP; since non-hydrolysable cAMP failed to induce 
differentiation while hydrolysis products of cAMP analogues induced stumpy 
formation more efficiently [111]. The downstream effector proteins targeted by the 
AMP signal in trypanosome are unknown. The closest T. brucei homologue for 
protein kinase A is not activated by cAMP in vitro [109, 112], and genes encoding G-
protein coupled receptors and heterotrimeric G-proteins are absent in T. brucei 
genome [109]. It is speculated the large family of transmembrane receptor-like 
adenylate cyclases (ACs) present in T. brucei could compensate for the missing 
receptor via their highly variable N-terminal extracellular domain. Several receptor-
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type flagellar ACs are developmentally regulated and show differential localization on 
the flagellum [113, 114]. So far no putative ligands for ACs are known, but depletion 
of insect stage specific adenylate cyclase 6 affected social motility [115]. This 
demonstrates a possible role for cAMP signaling in response to extracellular stimuli. 
In bloodstream forms, ACs belonging to the ESAG4 or ESAG4-like subfamily are 
required for cytokinesis [116].  
Additional cAMP signaling components driving stumpy formation were recently 
described in a genome-wide RNAi screen that selected trypanosomes resistant to 
SIF mimetics [117]. A putative RNA binding protein RBP7 was identified. When 
overexpressed in pleomorphic bloodstream forms, RBP7 promoted stumpy formation 
demonstrating that it is involved in normal quorum sensing. RBP7 mRNA targets and 
mechanism of action remains to be determined. Other factors identified from the 
screen included genes encoding purine metabolism proteins, kinases, phosphatases 
and several proteins of unknown function.   
 
1.6.2 Stumpy to procyclic forms transition  
The stumpy to procyclic form transition naturally occurs in the midgut of a tsetse fly. 
The decrease in temperature (from 37oC to ~20oC) experienced a few hours post 
ingestion sensitizes stumpy cells for signals to differentiate to procyclic forms. TCA 
cycle intermediate citrate/cis-aconitate (CCA) was identified [36, 118] as a possible 
physiological signal. The signal is perceived via a family of surface transporters 
known as the PAD proteins [119] expressed in stumpy forms. Cold shock at 20oC 
leads to increased (4x) PAD2 protein levels and relocation of PAD2 from the flagellar 
pocket to the cell surface [119]. This results to increased signal recognition when 
stumpy cells are incubated at 20oC, which enables differentiation induction with 
much less cis-aconitate (micromolar concentration instead of the usual 6mM at 27oC 
[36]); possibly reflecting conditions encountered in the tsetse fly midgut.  
A tyrosine phosphatase PTP1 prevents pre-mature differentiation of the short stumpy 
(Figure 1.6.2) by inhibiting a serine/threonine phosphatase PIP39 [120, 121]. The 
differentiation trigger citrate/cis-aconitate acts by inactivating PTP1, this together 
with cold shock leads to upregulation of phosphorylated PIP39 (active form) which in 
turn activates PTP1, creating a positive feedback loop [120]. Since PTP1 is located 
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in the cytoplasm/cytoskeleton, relocation of phosphorylated PIP39 to the glycosome 
prevents inactivation and ensures differentiation is irreversible. PIP39 
phosphorylation and glycosomal localization are required for differentiation since 
catalytically dead or localization impaired mutants are unable to rescue 
differentiation defects caused by PIP39 depletion [120]. The kinase responsible for 
PIP39 activation is unknown. Also, the substrates for PIP39 remain to be 
determined; perhaps PIP39 acts by regulating some of the metabolic activities in the 
glycosome.  
 
Figure 1.6.2 Model illustrating T. brucei phosphatase signaling cascade driving 
stumpy to procyclic form differentiation. The regulatory interactions are mostly based 
on in vitro data. Image taken from [120]. PAD= protein associated with 
differentiation, CCA= citrate/cis-aconitate. 
 
Apart from PTP1, the two kinases RDK1 and RDK2 act as repressors of 
differentiation in long slender bloodstream forms [122]. In contrast, the protein 
kinases MAPK5, ZFK, and TOR4 prevent premature differentiation to stumpy forms 
[123-125]; it remains to be determined whether they act individually or are part of a 
cascade. Stumpy to procyclic form differentiation can also be triggered by pronase, 
acting independently of PIP39 signaling [126].   
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1.7 RBPs regulating developmental changes in T. brucei 
Gene expression changes precede the profound morphological and metabolic 
changes observed during trypanosome differentiation. In the T. brucei stumpy to 
procyclic form transition, 69 genes are up regulated within one hour of differentiation 
initiation [127]; some of these genes encode proteins linked to mRNA metabolism, 
which is in accordance with post transcriptional mechanisms regulating gene 
expression in trypanosome. Several RNA binding proteins that are tightly regulated 
between life cycle stages have been shown to modulate developmental capacity in 
T. brucei [91, 92, 128]. Selected examples are described below.  
ALBA3 and ALBA4 are expressed in all T. brucei lifecycle stages apart from those 
found in the proventriculus of the tsetse fly [102]. Depletion of ALBA3/4 in procyclic 
forms slowed cell growth and resulted to a cellular morphology resembling that of the 
epimastigote while overexpression of ALBA3 in the tsetse fly impaired normal 
differentiation in the proventriculus [102]. Three zinc finger RBPs have been 
implicated in the T. brucei life cycle transition from bloodstream to procyclic form: 
ZFP1 is procyclic specific and is required for repositioning of the kinetoplast during 
stumpy-to-procyclic form differentiation [93]; ZFP2 is present in both bloodstream 
and procyclic forms and is important for efficient differentiation to the procyclic form 
[94]; and ZFP3 was found to bind EP1 and GPEET mRNAs that encode procyclic 
surface coat proteins, ZFP3 depletion decreased target mRNA levels and 
overexpression increased their translation [129]. RBP6 mRNA is up regulated in 
trypanosomes found in the proventriculus of the tsetse fly. Ectopic expression of 
RBP6 for ten days in procyclic forms allows production of epimastigotes and infective 
metacyclic forms [92]. In case of stumpy formation, overexpression of RBP7 in 
pleomorphic bloodstream form cells promoted pre-mature cell cycle arrest and 
increased capacity for differentiation to procyclic forms [117]. REG1, a putative RNA 
binding protein acts as a repressor of stumpy enriched mRNAs in the long slender 
bloodstream forms. Depletion of REG1 in long slender bloodstream form promoted 
stumpy formation in vivo independent of quorum sensing, whereas overexpression 
primed the cells to differentiate to procyclic forms [130]. REG1 and RBP7 mRNA 
targets remains to be determined.  
RBP10, which is the focus of this study; is a cytosolic RNA binding protein with a 
single RRM domain. RBP10 is expressed only in long slender bloodstream forms 
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where it is essential [91]; in stumpy and procyclic forms, RBP10 protein is 
undetectable [91, 105, 131]. Over-expression of RBP10 in pleomorphic bloodstream 
forms for 24 hours blocked in vitro differentiation to procyclic forms [91]. 
Transcriptome analysis revealed a widespread effect on gene expression upon 
alteration of RBP10 levels. In bloodstream forms, depletion of RBP10 led to up- 
regulation of procyclic specific mRNAs whereas mRNAs more abundant in 
bloodstream form cells were significantly down-regulated. A partial reversal of the 
transcriptome changes seen in bloodstream form occurred when RBP10 was over 
expressed in procyclic forms [91]. In both experiments, secondary effects due to 
growth inhibition could not be ruled out since mRNAs encoding several RNA binding 
proteins, as well as cytoskeleton and flagellum proteins were also significantly 
affected; these made it difficult to identify potential RBP10 mRNAs targets. 
Nonetheless, the transcriptome data indicated three possibilities; i) RBP10 acts as a 
positive regulator for the mRNAs more abundant in bloodstream forms, ii) RBP10 
could be a negative regulator for procyclic specific mRNAs that are highly unstable in 
long slender bloodstream forms, and iii) RBP10 does both functions mentioned 
above. The second option was strongly supported by two main findings: first, RBP10 
promoted reporter mRNA degradation and translation suppression when attached to 
the reporter 3’ UTR, second, RBP10 failed to comigrate with the translating 
polyribosomes after a sucrose density gradient centrifugation [91]. For the current 
study, we decided to investigate further how RBP10 acts as a negative regulator, 
and why that function is relevant in the bloodstream form life cycle stage. 
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1.8 Aim of the study 
The main goal for this project was to investigate RBP10 mechanism of action in 
order to understand how RBP10 modulates trypanosome gene expression and 
development. 
The specific objectives included: 
1. Identification of protein partners of RBP10 using genome wide yeast two hybrid   
screen and TAP purification.  
2. Investigating the early effects of RBP10 perturbation on global gene expression 
and translation using polysome profiling coupled to RNA sequencing.  
3. Identifying the target mRNAs and in vivo mRNA binding site of RBP10. 
4. Analyzing the role of RBP10 in differentiation regulation in Trypanosoma brucei. 
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2 Materials and methods 
2.1 Trypanosome cell culture and manipulation 
The experiments in this study were carried out using monomorphic T. brucei Lister 
427 bloodstream or procyclic form cells. The only exception is the differentiation 
studies where pleomorphic EATRO1125 cells were used. All the cell lines 
constitutively expressed the Tn10 tet repressor [132, 133].  
 
2.1.1  Bloodstream form culture 
Bloodstream form parasites were cultured at a density between 0.2-1.5x106 in HMi-9 
medium at 37oC with 5% CO2. 
The pleomorphic bloodstream EATRO1125 cells were maintained in the same 
conditions but diluted after every 24h to keep the cell density below 5x105 cells/ml. 
For stumpy forms generation, the pleomorphic bloodstream EATRO1125 cells were 
grown to high density (2-3x106 cells/ml) in HMI-9 medium with 1.1% methylcellulose 
and then left at the stationary phase for several days. 
 
HMi-9 medium [134]: 17.66 g/l Iscove’s modified Dulbecco’s medium, 3.024 g/l 
NaHCO3, 136 mg/l hypoxanthine, 110 mg/l sodium pyruvate, 39 mg/l Thymidine, and 
28 mg/l Bathocuprono disulfonic acid disodium salt. The media was filter sterilized 
and stored at 4oC in 450 ml aliquots. Prior to use the media was supplemented with 
10% (v/v) heat inactivated (30 min at 55oC) fetal bovine serum, 50 U/ml 
penicillin/streptomycin, 1.5 mM L-Cysteine-HCL.H2O, and 7 µl β-mercaptoethanol 
(14.1 M stock, sigma). 
 
HMI-9 medium with 1.1% methylcellulose, 1 litre: [123] 
    2X HMI-9    560 ml (complete with FCS, L-Cys, βME & PenStrep)  
    Methylcellulose    440 ml (2.5% in water) 
2.5% methylcellulose was prepared in water then dissolved by stirring at 4oC for 1-2 
days. After autoclaving and stirring at 4oC to re-dissolve, the volume was topped up 
using sterile water then further stirred (1-2 days, 4oC) to make sure it is completely 
dissolved. 
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2.1.2 Procyclic form culture 
The procyclic forms cells were maintained at a density between 0.5-5x106 cells/ml in 
MEM-Pros medium at 27oC. 
MEM-Pros medium: 16.55 g/l MEM-pros mixture (Biochrom), 1% (v/v) MEM non-
essential amino acids (sigma), 1% (v/v) MEM vitamins (sigma) and 10mg/l phenol 
red. The pH was adjusted to 7.4 using NaOH, the media was filter sterilized and 
stored in 450 ml aliquots at 4oC. Prior to use the media was supplemented with 10% 
(v/v) heat inactivated (30 min at 55oC) fetal bovine serum, 7.5mg/l Hemin and 
50U/ml penicillin/streptomycin (sigma).         
 
To dilute cells, the complete media was first pre-warmed in a water bath at 37oC for 
30min.      
 
2.1.3  Transfection of Bloodstream/procyclic trypanosomes 
For each transfection approximately 1-2x107 cells were used. The cells were washed 
twice using 0.4ml of the transfection buffer; for bloodstream forms (BS) the Amaxa-
buffer (90 mM NaH2PO4, 5 mM KCl, 0.15 mM CaCl2, 50 mM HEPS, pH 7.3 and for 
procyclics (PC) the ZPFM buffer (132 mM NaCl, 8 mM KCl, 8 mM Na2HPO4, 1.5 mM 
KH2PO4, 1.5 mM MgOAc.4H2O, 90 µM CaOAc2, pH 7.0).  
After washing, the cells were resuspended in the appropriate transfection buffer (100 
µl for BS, 400 µl for PC) and mixed with 10µg of linearized plasmid in a 2mm gap 
electroporation cuvette. Transfection of the bloodstream trypanosomes was 
performed using program X-001 of the Amaxa Nucleofactor (Lonza Cologne AG, 
Germany). For the procyclic forms the BTX electroporation machine (Harvard 
apparatus) was used with the settings of 1.5 KV and resistance R2. The cells were 
then transferred to 25 ml of pre-warmed medium and left overnight to recover. The 
following day, the selection antibiotics were added and the cells plated in serial 
dilution on a 24 well plate. For the pleomorphic EATRO1125 cells, 8 µg/ml 
hygromycin and 2 µg/ml blasticidin were used for selection.  
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For monomorphic bloodstream and procyclic forms the antibiotics concentrations are 
listed below. 
Antibiotic Bloodstream  Procyclic 
Blasticidin 5 µg/ml 10 µg/ml 
Neomycin/G418 5 µg/ml 15 µg/ml 
Hygromycin 15 µg/ml 50 µg/ml 
Phleomycin 0.2 µg/ml 0.2 µg/ml 
Puromycin 0.2 µg/ml 1 µg/ml 
 
Positive clones were identified 7-10 days later. After scaling up the cell numbers, the 
transgene expression for at least three independent clones was confirmed using 
Western blotting. Aliquots of the generated cell lines were frozen in appropriate 
medium with 10% glycerol and stored in liquid nitrogen.    
 
2.1.4 Cloning and Plasmids constructs  
Primers used for cloning (see section 2.9.2) were ordered from Biomers.net. 
Genomic DNA from T.brucei was isolated using illustra tissue and cells genomicPrep 
Mini Spin Kit (GE Healthcare). PCR was done using high fidelity Q5 DNA 
polymerase and buffer (NEB) according to the manufacturer’s instructions. The PCR 
product was digested with the appropriate restriction enzymes (NEB or Fermentas) 
and ligated to a plasmid with the same sticky ends. The ligation product was then 
transformed into competent E.coli DH5-alpha cells using heat shock at 42oC for 
1min. Positive clones were identified by colony PCR using GoTaq DNA polymerase 
(promega) and further confirmed by restriction digests after plasmid purification 
(Macherey-Nagel mini prep kit). Only one plasmid was selected for the final 
verification by Sanger DNA sequencing (GATC Biotech).  
The details of the plasmids and oligonucleotides used in this study are provided in 
section 2.9. 
 
2.1.5 Stable cell lines for inducible expression 
The tetracycline-inducible constructs for RBP10 RNAi and over expression have 
been described in [91]. The 4E-IP was ectopically expressed using the plasmid 
pHD2533. For the tethering assays, a lambdaN peptide was fused to RBP10 or six 
different fragments of the RBP10 open reading frame (ORF). The constructs were 
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separately transfected in a cell line constitutively expressing the CAT reporter with 
boxB actin 3’ UTR. Expression of the fusion protein was induced for 24h using 
tetracycline (100 ng/ml) and the levels of the CAT mRNA and CAT protein quantified 
using Northern blot and CAT assay respectively.  
 
2.1.6 Endogenous tagging of RBP10 
A cell line with in-situ TAP-RBP10 gene was generated by replacing one 
endogenous copy of RBP10 with a gene encoding N-terminally TAP tagged RBP10. 
To do this, a construct with puromycin resistance gene plus TAP tag cassette was 
flanked on the 5’ end with a fragment of RBP10 5’ UTR. Also, downstream on the 3’ 
end, the N terminal region of RBP10 ORF was cloned in frame with the TAP tag. 
Prior to transfection, the plasmid (pHD2506) was cut with Sac I and Apa I enzymes 
to allow homologous recombination. Using cells with in situ TAP-RBP10, the other 
copy of RBP10 was replaced with a knock out cassette (pHD2061) containing 
blasticidin resistance gene, and the absence of untagged RBP10 was confirmed by 
Western blotting. 
A similar approach was used for V5 in situ tagging; the construct used pHD1914 had 
a blasticidin resistance gene and in this case the knockout was not done.  
 
2.2 Tandem affinity purification (TAP)  
Approximately 2x1010 bloodstream form cells expressing either in-situ TAP-RBP10 
(pHD2506) or the tet-inducible GFP-TAP (pHD1743) were harvested and used for 
TAP as previously described [135]. Three biological replicates were done, with or 
without RNAse A treatment; triplicate results from the cells with inducible GFP-TAP 
served as background control. The cell pellet was lysed in 6 ml of lysis buffer (20 mM 
Tris pH7.5, 10 mM NaCl, 1× complete protease Inhibitor without EDTA (Roche), 
0.1% (v/v) IGEPAL) by passing 15-30 times through a 21G needle. The cell lysate 
was cleared by centrifugation at 15000 g for 10 minutes at 4oC. The supernatant was 
transferred to a new tube and NaCl adjusted to 150 mM. An aliquot (input sample) 
equivalent to ~5x106 cells was taken and 20 µl protein loading buffer added.  
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250µl IgG sepharose beads were transferred to a Bio-Rad column and pre-washed 
with 10 ml IPP150 buffer (20mM Tris pH 7.5, 150mM NaCl, 0.1% IGEPAL). The 
beads were then incubated (on a rotator) with the cleared lysate for 2h at 4oC. The 
unbound fraction was collected by gravity and an aliquot (flow through sample) 
equivalent to ~5x106 cells taken for further analysis. The beads were washed three 
times in IPP150 buffer and once using TEV cleavage buffer (IPP150 buffer plus 0.5 
mM EDTA and 1 mM DTT). The TEV cleavage was done overnight at 4oC using 150 
units of TEV protease (‘homemade’) in 1 ml TEV cleavage buffer. On the next day, 
the eluate was recovered by gravity and an aliquot (~1.5% of TEV eluate sample) 
taken for further analysis. 
 
250 µl of calmodulin affinity beads were transferred to a Bio-Rad column and 
washed with 10 ml calmodulin binding buffer (IPP150 buffer plus 10 mM β-
mercaptoethanol, 1 mM magnesium acetate, 1 mM imidazole, 2 mM CaCl2). 3 ul of 
1M CaCl2 was added to 3 ml of calmodulin binding buffer and then mixed with the 
eluate (~1ml) from the TEV cleavage. This sample was incubated with the pre-
washed calmodulin beads for 1.5h at 4oC. The beads were washed three times with 
the calmodulin binding buffer and the bound proteins eluted using calmodulin elution 
buffer (IPP150 buffer plus 10 mM β-mercaptoethanol, 1 mM magnesium acetate, 1 
mM imidazole, 2 mM EGTA). The eluate was concentrated by TCA precipitation, 
separated on a 10% SDS-polyacrylamide gel for only 2 cm and the proteins 
visualized by colloidal Coomassie staining. The gel area was excised and analysed 
by mass spectroscopy.  
 
2.3 Yeast two-hybrid screen 
The AH109 yeast strain (Clontech) was used. The cells were grown at 30oC in YPDA 
medium (20 g/l peptone, 10 g/l yeast extract, 2% gucose, 18 g/l agar (for plates), 
0.2% Adenine hemisulfate salt). For protein-protein interaction studies, the Match 
Maker Yeast-Two hybrid system (Clontech) was used according to manufacturer’s 
instructions. As bait, RBP10 ORF was cloned in frame with the yeast GAL4 DNA 
binding domain, with a myc tag on the N-terminus, using the pGBKT7 plasmid 
(pHD2361). For the prey, the RBP10 ORF was cloned into pGADT7 plasmid 
(pHD2368) which has GAL4 activation domain and an HA tag on the N-terminus.  
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Similar constructs were made for pairwise screens using two fragments of RBP10 
(F2 & F3) and the translation factors EF1-, EF2, eRF1, eRF3, eIF-5A and eIF-2B.  
 
2.3.1 Yeast transformation 
Fresh competent AH109 yeast cells were prepared by the LiAc method [136]. 
Pairwise analysis involved co-transformation with the bait and prey plasmids. Briefly, 
100 µl of competent AH109 cells was mixed with 200 ng of each plasmid DNA (prey 
and bait), 10 µl salmon sperm DNA (10mg/ml stock) and 600 µl PEG/LiAC solution 
(40% PEG 4000, 100mM LiAc, 1X TE buffer, pH 7.5). The cells were incubated at 
30oC (with shaking, 200rpm) for 30 min, and then heat-shocked in the presence of 
10% DMSO for 15 min at 420C. Positive clones were selected on SD quadruple 
drop-out medium (SD-QDO; minimal SD media lacking trypophan, leucine, adenine 
and histidine) and further confirmed phenotypically by growth (3-5 days) in presence 
of X-alpha-Gal substrate. The interaction between murine p53 and SV40 large T-
antigen served as positive control, with Lamin and SV40 large T-antigen as negative 
bait and prey controls. Protein expression was checked by Western blotting using 
the myc and HA tags for detection.  
 
2.3.2 Genome wide yeast two-hybrid screen and bioinformatics analysis  
RBP10 was used as a bait to screen a library made up of random genomic DNA 
fragments from T. brucei. The library was prepared by Dr. Esteban Erban [98]. For 
the screen, the library was transformed into AH109 yeast cells expressing pGBKT7-
RBP10. The positive clones were selected by growth on QDO medium for 5 days at 
30oC. 50 individual colonies were picked, checked by plasmid retransformation and 
the interacting partners sequences (prey plasmid) identified by Sanger DNA 
sequencing (GATC Biotech). The rest of the colonies were harvested en masse and 
the plasmid DNA isolated using plasmid mini prep kit (Macherey Nagel) after cell wall 
digestion using lyticase. To identify putative interacting partners, PCR amplification 
was carried out using pGADT7 vector-specific primers [98]. The PCR conditions; 
95oC for 2 min, 22 cycles of 95oC for 1 min, 57.5oC for 30 s, 72oC for 3 min and a 
final extension of 5 min at 72oC. To check the size distribution of the DNA smear, an 
aliquot of the PCR product was analyzed by agarose gel electrophoresis. Samples 
 30 
were purified and analyzed using high-throughput illumina sequencing (CellNetworks 
Deep Sequencing Core Facility at the University of Heidelberg and EMBL). The 
sequencing library was prepared using standard illlumina kits; libraries were 
multiplexed (6 samples per lane) and sequenced for 50 cycles on the illumina Miseq 
system. The high-throughput data was analyzed as described in [98]. Briefly, the 
insert-vector junction was identified and the vector sequence removed using custom 
made PERL scripts. The sequences were aligned to the T. brucei TREU 927 
reference genome using Bowtie [137], then sorted and indexed using SAMtools 
[138]. Sequences in-frame with an annotated ATG start codon and in-frame in the 5’ 
UTR were then selected and counted using SAMtools [138] and custom PERL 
scripts [98]. 
 
2.4 Cross-linking and RNA immunoprecipitation 
3x109 bloodstream form cells expressing in-situ TAP-RBP10 were concentrated in 20 
ml FCS-free media and then transferred to a petri dish (145 mm radius). The cells 
were irradiated on ice using UV (400 mj/cm2), washed in cold PBS and the cell pellet 
snap frozen in liquid nitrogen. The RNA immunoprecipitation was done as described 
in [139]. The cell pellet was lysed in 4 ml of the lysis buffer (10mM Tris pH7.5, 10mM 
NaCl, 2000U RNasin (Promega), 10 µg/ml leupeptin, 1× complete protease Inhibitor 
without EDTA (Roche), 0.1% (v/v) IGEPAL) by passing 15-30 times through a 21G 
needle. After centrifugation at 15000 g for 10 minutes at 4oC to remove the cell 
debris, the NaCl concentration was adjusted to 150 mM and the cell lysate incubated 
with 200 ul of pre-washed IgG sepharose beads for 2h at 4oC. The unbound fraction 
was collected, and beads washed three times in 10 ml of IPP150 buffer (20mM Tris 
pH 7.5, 150mM NaCl, 0.1% IGEPAL) and once in TEV cleavage buffer (IPP150 plus 
0.5 mM EDTA, 1 mM DTT, 200U/ml RNasin (Promega)). The TEV cleavage was 
done using 150 units of TEV protease (‘homemade’) in 1 ml TEV cleavage buffer 
and rotating the beads for 2h at 4oC. The eluate was collected by gravity and prior to 
RNA purification, the cross-linked protein was digested with  proteinase K (50 µg 
proteinase K, 8 mM EDTA, 0.2% SDS per 50 µl of the eluate) at 42oC for 15 minutes 
and the RNA isolated from both the bound and unbound fractions using Trifast 
reagent (Peqlab, GMBH). To assess the quality of the purified RNA, an aliquot of the 
sample was analysed by Northern blotting and the blot hybridized with a splice 
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leader probe. Total RNA from the unbound fraction was depleted of ribosomal RNA 
(rRNA) using RNAse H as described in [140] except that a cocktail of 50-base DNA 
oligos complementary to trypanosome rRNAs was used [141]. The recovered RNA 
from both bound and unbound samples was then analysed by RNA-seq. 
 
2.5 Polysome fractionation and RNA seq 
Approximately 3-5x108 cells were collected by centrifugation (850 x g, 10 minutes, 
21oC), and then treated in serum-free media with 100µg/ml cyclohexamide for 7 
minutes at room temperature. The pellet was washed in 1 ml ice cold PBS, lysed in 
350µl lysis buffer (20 mM Tris pH7.5, 20 mM KCl, 2 mM MgCl2, 1 mM DTT, 1000U 
RNasin (Promega), 10 µg/ml leupeptin, 100 µg/ml cycloheximide, 1× complete 
protease Inhibitor without EDTA (Roche), 0.2% (vol/vol) IGEPAL) by passing 15-30 
times through a 21G needle, followed by centrifugation (15000 x g, 10 minutes, 4oC) 
to clear the lysate. KCl was adjusted to 120 mM and the clarified lysate loaded on 
top of a 4 ml continuous linear 15-50% sucrose (w/v) gradient in polysome buffer 
(20mM Tris pH7.5, 120mM KCl, 2mM MgCl2, 1mM DTT, 10µg/ml leupeptin, 
100µg/ml cycloheximide). After 2 hours of ultracentrifugation (40000 rpm, 4oC; 
Beckman SW60 rotor), the samples were fractionated using Teledyne Isco Foxy Jr. 
system and the polysome profile recorded at 254 nm. 400 µl per fraction were 
collected and RNA isolated using Trifast reagent (Peqlab, GMBH). In the case of 
RBP10 tethering, lambdaN-RBP10 was induced (24h) and the distribution of the 
CAT reporter and alpha-tubulin mRNAs in the collected fractions detected by 
Northern blotting. 
For RNAseq, bloodstream form cells plus or minus RBP10 RNAi for 15h and, 
procyclic form cells with or without RBP10-myc over-expression for 6h were used. In 
this case 250 µl fractions were collected from each gradient and RNA was isolated 
after pooling the fractions into two groups; i) lighter fractions including monosomes, 
ii) denser fractions with at least two ribosomes. The amount of mRNA in the pooled 
samples was assessed by Northern blotting using splice leader RNA as probe. Also, 
total RNA was prepared from the input samples (~10% of total cell lysate) to quantify 
changes in the steady state mRNAs levels. All samples were depleted of rRNAs (as 
above) prior to analysis by RNA-seq. 
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2.5.1 High throughput RNA sequencing and bioinformatic analysis  
RNA-seq was done at the CellNetworks Deep Sequencing Core Facility at the 
University of Heidelberg. For library preparation, NEBNext Ultra RNA Library Prep 
Kit for Illumina (New England BioLabs Inc.) was used. The libraries were multiplexed 
(6 samples per lane) and sequenced with a HiSeq 2000 system, generating 50 bp 
single-end sequencing reads. 
The quality of the raw sequencing data was checked using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc), and the sequencing 
primers removed using Cutadapt software [142]. The data was aligned to T. brucei 
TREU 927 reference genome using Bowtie [142], then sorted and indexed using 
SAMtools [138]. Reads aligning to open reading frames of the TREU 927 genome 
were counted using custom python scripts. Analysis for differentially expressed 
genes was done in R software using the DESeq2 package [143] with an adjusted p-
value cut-off of 0.05. The wild-type transcriptome datasets from [144] was used to 
generate the list of developmentally regulated trypanosome mRNAs with a 2-fold cut-
off. Comparative analysis was limited to the unique genes list [145]; for the RNA pull 
down, a minimum of 3-fold enrichment (bound versus unbound) in both replicates 
was was used as the cut-off. Categories enrichment between the datasets was 
checked using Fisher’s exact test. The 3’ UTR motif enrichment search was done 
using DREME [146]; annotated 3’ UTR sequences were downloaded from tritrypDB 
and we considered only the mRNAs with 3’ UTRs >20 nt.  
 
For de novo assembly, the SPAdes [147] genome assembler was used. Contigs 
having the ‘TGATATATTTTAAC’ motif present in the 3’ UTR of all VSG mRNAs were 
identified and analysed using the VSG identification tool 
(https://github.com/klprint/IdentifyVSGs). The random shotgun reads from the 
EATRO1125 genome were obtained from [148]; only contigs of 4 kb and longer were 
considered for metacyclic promoter identification. 
 
2.6 Analysis of reporters containing EP1 3’ UTR  
The bloodstream form cells expressing the CAT reporter with either full length EP1 3’ 
UTR (pHD1610) or a mutant version (pHD1611) lacking the 26mer (EP1∆26) 
instability element were used for RNA immunoprecipitation using anti-RBP10 [91] 
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antibody. For the pull down, 4x108 cells were irradiated on ice using UV (400 
mj/cm2), washed in cold PBS and the cell pellet lysed in 350 µl lysis buffer (10mM 
Tris pH 7.5, 10mM NaCl, 1000U/ RNasin (Promega), 1× complete protease Inhibitor 
without EDTA (Roche), 0.1% IGEPAL) by passing 15 times through a 21G needle. 
The lysate was cleared by centrifugation at 15000 g for 10 minutes at 4oC, NaCl was 
adjusted to 150 mM followed by incubation with 50 µl anti-RBP10 coupled agarose 
beads for 2h at 4oC. After washing the beads 5 times with IPP150 buffer (10 mM Tris 
pH 7.5, 150 mM NaCl, 0.1% IGEPAL), the beads were treated with proteinase K (50  
µg proteinase K, 8 mM EDTA, 0.2% SDS per 50 µl of the beads) at 42oC for 15 
minutes and RNA was isolated from both bound and unbound fractions using Trifast 
reagent (peqlab, GMBH). Equal amounts of the recovered RNA (eluate and flow 
through fractions) were reverse-transcribed into cDNA using RevertAid First Strand 
cDNA Synthesis Kit (Thermal Scientific) according to the manufacturer’s instructions. 
2 µl of the cDNA was used as template in a 50 µl PCR reaction to detect the CAT 
and alpha-tubulin genes. PCR was done using Q5 DNA polymerase and buffer 
(NEB) with 0.5µm of the following primers, for CAT (CZ5725; CZ689) and alpha-
tubulin (CZ5725; CZ6168); the forward primer is identical since it anneals to the 
splice leader. Aliquots (10 µl) were removed after the 27, 31 and 36 cycles and 
analysed using agarose gel electrophoresis. 
To determine if the regulation of the EP mRNA by RBP10 depends on the 26mer 
instability element, a stem-loop construct (pHD1984) targeting RBP10 was 
transfected in the two cell lines. RBP10 RNAi was induced using 100 ng/ml 
tetracycline for 17h or 24h and the levels of the CAT protein monitored using the 
CAT assay. 
 
2.6.1 CAT assay  
Chrolamphenicol acetyl transferase (CAT) activity was measured in a kinetic assay. 
It involves the transfer of an acetyl group from radiolabelled 14C butyrl CoA to 
chrolamphenicol. The 14C butyrl-chrolamphenicol becomes water insoluble and 
moves from the aqueous to the organic phase of the scintillation fluid.  
 
For the CAT assay, 15x106 cells expressing the CAT reporter were harvested (900 g 
for 5 min), washed once in PBS and the cell pellet resuspended in 200 µl of CAT 
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assay buffer (100mM Tris-HCL, pH 7.8). The cells were lysed by freeze-thawing 
three times in liquid nitrogen. After centrifugation at 15000 g for 3 min at 40C, the 
supernatant was transferred to a new tube and the total protein concentration 
measured by Bradford method. For longer storage the samples were kept at -80oC. 
BSA concentrations 0, 1, 2, 4, 8, 12, 16, 20 µg (100 µg/ml stock) in 800 µl of water 
were used to generate the Bradford’s standard curve. To each, 200 µl of Bradford 
reagent (BioRad) was added, the samples were incubated for 5 min at room 
temperature and the OD was measured at 595 nm in a spectrophotometer (BioRad). 
In the case of the cell lysate samples, 5 µl was used for the Bradford measurement. 
To measure the CAT activity 0.5-1 µg of total protein were scaled up to 50 µl using 
the CAT assay buffer. After addition of 2 µl chloramphenicol (40 mg/ml stock), 10 µl 
14C butryl CoA, 200 µl CAT assay buffer and 4 ml scintillation solution (Econfluor-2), 
the samples were analyzed after every 12-16 min for 1.5h in a scintillation counter 
(Beckman LS6000IC; using program 7) to detect 14C. Once plotted, the data slope at 
the linear range (before saturation) was compared between samples to estimate the 
relative CAT protein levels. 
 
2.6.2 Northern blotting  
Total RNA was isolated (for solid and liquid samples) using Trifast reagent (peqlab, 
GMBH) according to manufacturer’s instructions. The purified RNA was separated 
on formaldehyde agarose gel and blotted onto Nytran membranes (GE Healtcare). 
Detection was done using radioactively labeled DNA probes (Random Primer 
Labelling Kit, Stratagene) for CAT, alpha-tubulin mRNAs, and for total RNA an 
oligonucleotide (CZ4490) antisense to mini-exon. The signal was measured using 
phosphorimager (Fuji, FLA7000) and the quantification done using MultiGauge 
software.  
 
2.7 Trypanosome differentiation 
Pleomorphic EATRO1125, bloodstream form were used. For stumpy differentiation, 
the cells were maintained in HMi-9 with 1.1% methylcellulose and left to grow for 3-5 
days without dilution to reach the stationary phase. The cell culture was diluted 1:5 
with pre warmed PBS, filtered through MN616 ¼ filter papers (Macherey Nagel) 
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followed by centrifugation at 1400 g for 10 min. The cells were resuspended in HMi-9 
medium without methylcellulose; differentiation was induced using 6mM cis-aconitate 
and incubation at 27oC. After 17h, the cells were harvested, resuspended (5-7 x 105 
cells/ml) in MEM-pros medium and maintained at 27oC. The expression of the 
stumpy form marker PAD1 was checked by Western blotting. 
 
2.7.1 RBP10 mediated trypanosome differentiation  
Pleomorphic EATRO1125 bloodstream form cells expressing the Tet-repressor were 
transfected with a stem-loop construct (pHD1984) targeting RBP10. The growth of 
the cells was monitored for 3 days with and without RBP10 RNAi. Differentiation to 
procyclic forms was done by depleting RBP10 for 17 hours; the cells were pelleted, 
resuspended (~8x105 cells/ml) in procyclic form (MEM-pros) medium and incubated 
at 27oC. As positive controls, wild type or uninduced cells (2x106 cells/ml) were 
treated with 6mM cis-aconitate (Sigma) at 27oC, after 17h the cells were transferred 
into procyclic form media (~8x105 cells/ml) and maintained at 27oC. The cell density 
was monitored after 0, 6, 10, 24, 48, and 72 hours, samples (~5x106) were taken at 
each time point and the expression levels of EP, PIP39 and RBP10 proteins 
analysed by Western blot. 
 
To convert procyclic to bloodstream forms, EATRO1125 bloodstream form cells with 
an inducible RBP10-myc construct (pHD2098) were differentiated to procyclic forms 
using cis-aconitate as described above. The cells were cultured in presence of 
hygromycin (8µg/ml) and phleomycin (0.2µg/ml) for more than 3 months to generate 
well-established procyclic forms. RBP10-myc was induced using 100ng/ml 
tetracycline, the growth of the cells was monitored for 3 days and the protein levels 
of EP, PIP39, RBP10, hnRNPH , TAO and BARP detected by Western blot. The 
presence of the VSG transcripts was detected by semiquantitative RT-PCR as 
previously described in [92] using primers CZ6308/CZ6309. To generate blood 
stream forms, RBP10-myc was induced for 48 hours, the cells were pelleted, 
resuspended (2x105) in HMI-9 medium and incubated at 37oC with 5% CO2. The cell 
density was monitored for 6 days; wild type or uninduced cells served as control.  
 
 36 
2.7.2 Analyses of cell morphology and differentiation markers expression 
DAPI stained cells were analysed by microscopy and the distance between the 
kinetoplast (K), nucleus (N) and posterior cell end measured using Fiji [149]. The 
switch of the surface coat proteins EP, GPEET and VSG was analysed by indirect 
immunofluoresence and FACS. Also, the differential localization of PGK protein was 
used to distinguish the bloodstream forms cells from the procyclic forms.  
 
2.7.2.1 Indirect Immunofluorescence 
2x106 cells were collected by centrifugation, re-suspended, then fixed in 4% 
paraformadehyde (in 1x PBS) for 18 minutes, sedimented again for 2 minutes, re-
suspended in PBS and allowed to settle on poly-L-lysine coated slides for 30 
minutes. Before staining, slides were blocked with 20% fetal calf serum (1x PBS) for 
20 minutes. To detect the PGK protein, cells were permeabilised with 0.2% (v/v) 
Triton-X 100 (in 1xPBS) for 15 minutes at room temperature, washed twice then 
incubated for one hour with rabbit anti PGK antibody (1:1500; [150]). For the surface 
coat proteins, the cells were fixed in 100% methanol at -20oC for 15 minutes, 
rehydrated in 1x PBS for 15 minutes, blocked for 20 minutes with 20% FCS, then 
labeled with mouse anti EP (1:500; Cedarlane, Canada), mouse anti phospho-
GPEET (1:500; Cedarlane, Canada) and rabbit anti VSG-117 (1:500; kind donation 
from GA. cross) antibodies. The cells were washed 3 times before being stained with 
fluor-conjugated secondary antibody (1:500; mouse-Cy3 or rabbit-Alexa-488; 
Molecular probes, Eugene). Cellular DNA was stained with 100ng/ml DAPI in 1x 
PBS for 15 minutes. Images were taken using Olympus Cell-R microscope. 
I took snapshots of random fields then Prof. Christine Clayton did the measurement 
and analysis of the K-N distances. 
 
2.7.2.2 Flow cytometry 
Approximately 5x106 cells were fixed with 2% formaldehyde/0.05% glutaraldehyde at 
4oC for at least 1 hour. The cells were pelleted, washed twice with PBS then 
incubated with 200 µl (2% BSA in PBS) mouse anti-EP (Caderlane, Canada; 1:500) 
or rabbit anti-VSG-117 (1:500; from either G. cross or P. Overath) for one hour on 
ice. After washing twice, the cells were stained with the secondary antibody (1:500; 
 37 
mouse-Cy5 or rabbit-Alexa-488; Molecular probes, Eugene) for one hour. Cells 
stained only with the secondary antibody and the unstained cells served as the 
negative controls. Flow cytometry was performed with BD FACSCanto II flow 
cytometer and the data analysed using FlowJo software (TreeStar Inc.).  
 
2.8 Protein detection 
Proteins were detected by Western blotting according to standard protocols. The 
only exception was PAD1 protein detection. In this case, the samples were not heat 
denatured and the SDS-PAGE gel was run at 4oC using pre chilled buffers.  
The following antibodies were used; anti-c-myc (mouse, 1:1000, Santa Cruz 
Biotech), anti-v5 (mouse, 1:1000, BioRad), anti-aldolase (rabbit 1:50000), anti-TR 
(rabbit 1:1000, from L. Siegel lab), anti-RBP10 (rat, 1:2000, [91]), anti-hnRNPH 
(rabbit,1:5000, [151]), anti-TAO (rabbit,1:100, [150]), anti-EP (mouse,1:2000, 
Cedarlane, Canada), anti-GPEET (mouse,1:2000, Cedarlane, Canada), anti-BARP 
(rabbit,1:2500, [42]), anti-PIP39 (rabbit,1:1000, [152]) and anti-PAD1 (rabbit, 1:1000, 
[153]). The secondary antibodies (1:2000, GE Healthcare) used were coupled to 
HRP, and the signal was detected using ECL solutions. 
 
For the co-immunoprecipitation (co-IP), the sample lysis and immunoprecipitation 
was performed as described in section 2.6; without UV irradiation of cells and 
proteinase K treatment. 50 µl anti-myc or anti-V5 coupled agarose beads was used 
for immunoprecipitation. 
 
 
2.9 List of plasmids and Oligonucleotides used 
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2.9.1 Plasmids list 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid No. Description Primers 
Resistance  
marker 
Plasmid 
backbone 
Ectopic inducible expression from rDNA locus 
  
  
  
pHD1984 Stem-loop against RBP10 Wurst et al 2012 HgrR pHD1146 
pHD2098 RBP10-myc Wurst et al 2012 HgrR pHD1700 
pHD2276 LambdaN-RBP10 (full length) Wurst et al 2012 HgrR pHD1743 
pHD2422 LambdaN-RBP10-F1-myc (positions 48-306a.a.) cz4942; cz4943 HgrR pHD2202 
pHD2421 LambdaN-RBP10-F2-myc (positions 1-218a.a.) cz4940; cz4941 HgrR pHD2202 
pHD2457 LambdaN-RBP10-F3-myc (positions 218-306a.a.) cz5008; cz4943 HgrR pHD2202 
pHD2471 LambdaN-RBP10-F4-myc (positions 123-218a.a.) cz5006; cz5007 HgrR pHD2202 
pHD2504 LambdaN-RBP10-F5-myc (positions 218-262a.a.) cz5008; cz5085 HgrR pHD2202 
pHD2505 LambdaN-RBP10-F6-myc (positions 262-306a.a.) cz5086; cz4943 HgrR pHD2202 
pHD2533 4E-IP-myc cz5253; cz5063 HgrR pHD1700 
pHD2734 DRBD13-myc 
Bhaskar et. al 
2015 Hgr pHD1700 
pHD2813 Stem-loop against 4E-IP cz5644; cz5645 HgrR pHD1146 
Single knockout 
  
  
  
pHD2061 3’ and 5’ UTR RBP10 +Blasticidin resistance cassette 
cz5180;cz5181  
cz5182; cz5183 BlasR pHD1748 
In situ tagging 
  
  
  
pHD 2506 In situ N-TAP-RBP10 
cz5128;cz5129  
cz5130; cz5131 PuroR pHD1959 
pHD 2845 In situ N-BirA-RBP10 cz6197;cz6198 PuroR pHD2506 
pHD 1914 In situ V5-RBP10 
cz4952;cz4953  
cz4954; cz4955 BlasR Bla-V5 
pHD2393 In situ V5-RBP26 
cz4952;cz4953  
cz4954; cz4955 BlasR Bla-V5 
pHD2735  In situ V5-DRBD13 Bhaskar et al 2015 BlasR Bla-V5 
CAT reporter 
  
  
  
pHD1610 CAT + EP1 3’UTR (pT7-CAT- EP1 3'UTR) Schwede et al PuroR Schwede et al 
pHD1611 CAT +EP1∆26 3’UTR (pT7-CAT-EP1∆26 3'UTR) Schwede et al PuroR Schwede et al 
pHD 2277 CAT with 5 boxB + Actin 3'UTR Delhi et al 2011 NeoR Delhi et al 2011 
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Plasmid No. Description Primers 
Resistance  
marker 
Plasmid 
backbone 
Yeast two hybrid 
pHD2361 RBP10 ORF cloned in pGBKT7 (N-terminus myc) cz4598;cz4599 KanR & TRP1 pGBKT7 
pHD2368 RBP10 ORF cloned in pGADT7 (N-terminus HA) cz4598;cz4599 AmpR & LEU2 pGADT7 
pHD2585 RBP10-F3    cloned in pGBKT7 (N-terminus myc) cz5223;cz5224 KanR & TRP2 pGBKT7 
pHD2586 RBP10-F3    cloned in pGADT7 (N-terminus HA) cz5223;cz5224 AmpR & LEU3 pGADT7 
pHD2587 RBP10-F2    cloned in pGBKT7 (N-terminus myc) cz5254;cz5255 KanR & TRP2 pGBKT7 
pHD2588 RBP10-F2    cloned in pGADT7 (N-terminus HA) cz5254;cz5255 AmpR & LEU3 pGADT7 
pHD2490 4E-IP ORF cloned in pGBKT7 (N-terminus myc) cz5048;cz5049 KanR & TRP3 pGBKT7 
pHD2489 4E-IP ORF cloned in pGADT7 (N-terminus HA) cz5048;cz5049 AmpR & LEU4 pGADT7 
pHD2362 EF-1 alpha ORF cloned in pGBKT7 (N-terminus myc) cz4602;cz4603 KanR & TRP3 pGBKT7 
pHD2369 EF-1 alpha ORF cloned in pGADT7 (N-terminus HA) cz4602;cz4603 KanR & TRP2 pGADT7 
pHD2363 EF-2   ORF cloned in pGBKT7 (N-terminus myc) cz4604;cz4605 AmpR & LEU3 pGBKT7 
pHD2370 EF-2   ORF cloned in pGADT7 (N-terminus HA) cz4604;cz4605 KanR & TRP3 pGADT7 
pHD2364 eRF-1 ORF cloned in pGBKT7 (N-terminus myc) cz4606;cz4607 AmpR & LEU4 pGBKT7 
pHD2371 eRF-1 ORF cloned in pGADT7 (N-terminus HA) cz4606;cz4607 KanR & TRP3 pGADT7 
pHD2365 eRF-3 ORF cloned in pGBKT7 (N-terminus myc) cz4608;cz4609 AmpR & LEU4 pGBKT7 
pHD2372 eRF-3 ORF cloned in pGADT7 (N-terminus HA) cz4608;cz4609 KanR & TRP4 pGADT7 
pHD2366 eIF-5A ORF cloned in pGBKT7 (N-terminus myc) cz4610;cz4611 AmpR & LEU5 pGBKT7 
pHD2373 eIF-5A ORF cloned in pGADT7 (N-terminus HA) cz4610;cz4611 KanR & TRP4 pGADT7 
pHD2367 eIF-2B ORF cloned in pGBKT7 (N-terminus myc) cz4612;cz4613 KanR & TRP3 pGBKT7 
pHD2374 eIF-2B ORF cloned in pGADT7 (N-terminus HA) cz4612;cz4613 AmpR & LEU4 pGADT7 
pHD2394 RBP26 ORF cloned in pGBKT7 (N-terminus myc) 
 
KanR & TRP1 pGBKT7 
pHD2395 DRBD12 ORF cloned in pGBKT7 (N-terminus myc) 
 
KanR & TRP1 pGBKT7 
pHD2396 ZC3H22 ORF cloned in pGBKT7 (N-terminus myc) 
 
KanR & TRP1 pGBKT7 
pHD2397 Tb927.10.10050 ORF cloned in pGBKT7 (N-terminus myc) 
 
KanR & TRP1 pGBKT7 
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Plasmid No. Description Primers 
Resistance  
marker 
Plasmid 
backbone 
IPTG inducible expression  
pHD2618 pHD359 with Lac repressor + neomycin marker    cz5554; cz5555 NeoR pHD 389 
pHD2700 pHD359 with Lac repressor + blastcidin marker   cz5749; cz5750 BlasR pHD 389 
pHD2659 pHD 1034 with 2x Lac operator + PuroR from pHD1336 cz5582; cz5583 PurR pHD 1034, 1336 
pHD2661 pHD2659 + RBP10 (no tag)    PurR pHD 2659  
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2.9.2 Oligonucleotides list 
Oligo No. Description 
Restriction 
site 
Sequence Purpose 
Cloning primers  
cz4598 Fwd-RBP10 ORF (pHD2361; pHD2368) NdeI TAGACTCATATGGGAGACTCGATATCACCT Y2H-bait/prey (RBP10) 
cz4599  Rev-RBP10 ORF (pHD2361; pHD2368) EcoRI TATAGAATTCTCACTCCATTCGAACCGGA Y2H-bait/prey (RBP10) 
cz5223 Fwd-RBP10 ORF-F3  (pHD2585; pHD2586) NdeI TATACATATGGGTGCAGGGGTCACACAA Y2H-bait/prey (RBP10-F3) 
cz5224 Rev-RBP10 ORF-F3  (pHD2585; pHD2586) EcoRI TATAGAATTCTCCCATTCGAACCGG Y2H-bait/prey (RBP10-F3) 
cz5254 Fwd-RBP10 ORF-F2  (pHD2587; pHD2588) NdeI TATACATATGATGGGAGACTCGATATCA  Y2H-bait/prey (RBP10-F2) 
cz5255 Rev-RBP10 ORF-F2  (pHD2587; pHD2588) EcoRI TATAGAATTCGTGAATTGGCGCTTGCAT Y2H-bait/prey (RBP10-F2) 
cz4602 Fwd-EF1 ORF  (pHD2362; pHD2369) NdeI TATACATATGGGAAAGGAAAAGGT Y2H-bait/prey (EF1) 
cz4603 Rev-EF1 ORF  (pHD2362; pHD2369) EcoRI TATAGAATTCTTATTTCTTCGAAGCCTTC Y2H-bait/prey (EF1) 
cz4604 Fwd-EF2 ORF  (pHD2363; pHD2370) NdeI TATACATATGGTCAACTTCACCGT Y2H-bait/prey (EF2) 
cz4605 Rev-EF2 ORF  (pHD2363; pHD2370) EcoRI TATAGAATTCCTATAGCTTGTCCAGGAAG Y2H-bait/prey (EF2) 
cz4606 Fwd-eRF1 ORF  (pHD2364; pHD2371) NdeI TATACATATGGCCGACCACGAGT Y2H-bait/prey (eRF1) 
cz4607 Rev-eRF1 ORF  (pHD2364; pHD2371) EcoRI TATAGAATTCTTACATAAAGTCGTCGTCGAA Y2H-bait/prey (eRF1) 
cz4608 Fwd-eRF3 ORF  (pHD2365; pHD2372) NdeI TATACATATGTCAGGTTGGGCAC Y2H-bait/prey (eRF3) 
cz4609 Rev-eRF3 ORF  (pHD2365; pHD2372) EcoRI TATAGAATTCTTAAGCTTTACCTGCGTTC  Y2H-bait/prey (eRF3) 
cz4610 Fwd-eIF5A ORF (pHD2366; pHD2373) NdeI TATACATATGTCTGACGATGAGGG Y2H-bait/prey (eIF5A) 
cz4611 Rev-eIF5A ORF (pHD2366; pHD2373) EcoRI TATAGAATTCTTATCGCTCAGCTGCAT  Y2H-bait/prey (eIF5A) 
cz4612 Fwd-eIF2B ORF  (pHD2367; pHD2374) NdeI TATACATATGCTTTCATGTTCCTGT Y2H-bait/prey (eIF2B) 
cz4613 Rev-eIF2B ORF (pHD2367; pHD2374 EcoRI TATAGAATTCCTACTGGCATTTCCCC Y2H-bait/prey (eIF2B) 
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Oligo No. Description 
Restriction 
site 
Sequence Purpose 
Cloning primers  
cz5253 Fwd-4EIP ORF (pHD2533) HpaI TGACGTTAACATGAGAACTACAATTCGA ectopic-4EIP-myc 
cz5063 Rev-4EIP ORF (pHD2533) BamHI GACGGATCCGCGGCGCTGGTTGGG ectopic-4EIP-myc 
cz4942 Fwd-RBP10 ORF-F1 (pHD2422) ApaI TATAGGGCCCCGTAACGTTTATGTCTCT tethering_F1 
cz4943 Rev-RBP10 ORF-F1 (pHD2422) BamHI TATAGGATCCCTCCATTCGAACCGGAGG tethering_F1 
cz4940 Fwd-RBP10 ORF-F2 (pHD2421) ApaI TATAGGGCCCATGGGAGACTCGATATCA tethering_F2 
cz4941 Rev-RBP10 ORF-F2 (pHD2421) BamHI TATAGGATCCGTGAATTGGCGCTTGCAT tethering_F2 
cz5008 Fwd-RBP10 ORF F3 (pHD2457) ApaI TATAGGGCCCGGTGCAGGGGTCACACAA tethering_F3 
cz5006 Fwd-RBP10 ORF F4 (pHD2471) ApaI TATAGGGCCCATAGCAGACGCCGCTGCA tethering_F4 
cz5007 Rev-RBP10 ORF F4 (pHD2471) BamHI TATAGGATCCGTGAATTGGCGCTTGCAT tethering_F4 
cz5085 Rev-RBP10 ORF F5 (pHD2504) BamHI TATAGGATCCAGTCACAAATAGAGGCAT tethering_F5 
cz5086 Fwd-RBP10 ORF F6 (pHD2505) ApaI TATAGGGCCCATGCCACAAACCGCGCCC tethering_F6 
cz5128 Fwd-RBP10-5’UTR (pHD2506) SacI TATAGAGCTCATCTTGGTGTTCCATACG insitu_N_TAP_RBP10 
cz5129 Rev-RBP10-5’UTR (pHD2506) NdeI TATACATATGCTTACAGATGTTTGTCAA insitu_N_TAP_RBP10 
cz5130 Fwd-RBP10-miniORF (pHD2506) HindIII TATCAAGCTTCCATGGGAGACTCGATATCA insitu_N_TAP_RBP10 
cz5131 Rev-RBP10-miniORF (pHD2506) ApaI TATAGGGCCCCGGCCGCCCATAAGCACT insitu_N_TAP_RBP10 
cz5180 Fwd-RBP10-3’UTR (pHD2061) EcoRI TATAGAATTCTGGCACAGAGGGTAACGA SKO_rbp10-3’ 
cz5181 Rev-RBP10-3’UTR (pHD2061) BamHI TATAGGATCCGGCCTGTCTTCCTTCCTC SKO_rbp10-3’ 
cz5182 Fwd-RBP10-5’UTR (pHD2061) XhoI TATACTCGAGTACCGAATCTGACCTTTC SKO_rbp10-5’ 
cz5183 Rev-RBP10-5’UTR (pHD2061) HindIII TATTAAGCTTCTTACAGATGTTTGTCAA SKO_rbp10-5’ 
cz4952 Fwd-RBP10-miniORF (pHD1914) XhoI TATACTCGAGATGGGAGACTCGATATCA insitu_v5_RBP10 
cz4953 Rev-RBP10-miniORF (pHD1914) ApaI TATAGGGCCCTTAAGTCCTTCGATGCAC insitu_v5_RBP10 
cz4954 Fwd-RBP10-5’UTR (pHD1914) SacII TATACCGCGGATCTTGGTGTTCCATACG insitu_v5_RBP10 
cz4955 Rev-RBP10-5’UTR (pHD1914) XbaI TATATCTAGACTTACAGATGTTTGTCAA insitu_v5_RBP10 
Cz4804 Fwd-RBP26-miniORF (pHD1914) XhoI TATACTCGAGATGGAAACGCACCAGGAT insitu_v5_RBP26 
Cz4805 Rev-RBP26-miniORF (pHD1914) ApaI TATAGGGCCCAGTGGCTTGCGTGACACG insitu_v5_RBP26 
Cz4802 Fwd-RBP26-5’UTR (pHD1914) SacII TATACCGCGGTGTCCTGCTTGTGTGGCG insitu_v5_RBP26 
Cz4803 Rev-RBP26-5’UTR (pHD1914) XbaI TATATCTAGAGACTAAGGGAGGAGAATC insitu_v5_RBP26 
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Oligo No. Description 
Restriction 
site 
Sequence Purpose 
Cloning primers  
cz5554 Fwd-Neomycin ORF SpeI TATAACTAGTGATGGTGGAACAAGATGGATT 
subcloning neomycin+ 
aldolase_3' UTR 
cz5555 Rev-Aldolase 3' UTR StuI CCTTCGAATCCCCCCATTTTCTT 
subcloning neomycin+ 
aldolase_3' UTR 
cz5749 Fwd-Blasticidin ORF SpeI TATCACTAGTATGGCCAAGCCTTTGTCTC 
subcloning blasticidin+ 
actin_3' UTR 
cz5750 Rev-Actin 3' UTR StuI TATAAGGCCTTGCAGAATACTGCATAGAT 
subcloning blasticidin+ 
actin_3' UTR 
cz5582 2x Lac operator forward oligo 
SmaI  
blunted 
GGAATTGTGAGCGGATAACAATTCGGAATT- 
GTGAGCGGATAACAATTCCC Lac operator 2 copies 
cz5583 2x Lac operator complementary oligo 
SmaI 
blunted 
CCTTAACACTCGCCTATTGTTAAGCCTTAA- 
CACTCGCCTATTGTTAAGGG 
Lac operator 2 copies 
 (complementary) 
cz6197 Fwd-BirA ORF XhoI TATACTCGAGCCATGAAGGATAATACTGTTCC insitu_BirA_RBP10 
cz8198 Rev-BirA ORF HindIII TATTAAGCTTGAGCAGCAGCAGAAATTTGAAC insitu_BirA_RBP10 
Primers for Northern blot probes  
cz4615 CAT probe Fwd   ATGGAGAAAAAAATCACTGGATAT CAT probe 
cz2689 CAT probe Rev   GAAAGACGGTGAGCTGGT CAT probe 
cz2724 tubulin probe Fwd   TGACTCGCCGCAACCTCGAT Tubulin probe  
cz2581  tubulin probe Rev   CCTTTGGCACAACGTCACCACGG Tubulin probe  
cz4490 spliced leader oligo (antisense)   
CAATATAGTACAGAAACTGTTCTAATAATA- 
GCGTTAGTT splice leader  probe 
Semi-quantitative RT-PCR primers 
cz5725 spliced leader Fwd   ACGCTATTATTAGAACAGTTTCTGTAC RT-PCR 
cz689 CAT ORF Rev   GAAAGACGGTGAGCTGGT RT-PCR 
cz6168 tubulin ORF Rev   CAGCCTGACCAATGTGGATGCAGAT RT-PCR  
cz6308 spliced leader Fwd   GACTAGTTTCTGTACTAT RT-PCR  
cz6309 All VSGs Rev   CCGGGTACCGTGTTAAAATATATC RT-PCR  
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3 Results 
3.1 RBP10 C-terminus promotes reporter mRNA destruction and inhibits 
translation 
To determine the effect that RBP10 has on bound mRNAs, the lambda N peptide 
was used to artificially tether RBP10 to a CAT reporter bearing five boxB recognition 
sites and the actin 3’UTR (Figure 3.1 A-i). As a control, we used a cell line lacking the 
fusion protein. Reduction in CAT protein was observed in some of the uninduced 
samples, probably because of leaky expression of the fusion proteins (Figure 3.1 A-ii, 
C). As previously reported [91], full length RBP10 when tethered repressed the CAT 
reporter expression; the amount of protein was ~90% reduced, CAT mRNA 
abundance was slightly less affected with ~40% being detected. Surprisingly, 
untagged RBP10 was reduced after 24 hours of λN-RBP10 expression (Figure 3.1 A-
ii); cell growth was also affected. 
 
 
Figure 3.1 RBP10 tethering in bloodstream form trypanosomes. A) Part (i) the 
λN/boxB interaction system used for tethering. The CAT reporter was constitutively 
expressed, and had 5 copies of boxB sequences (for simplicity only one is shown) 
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upstream of the actin 3’ UTR. (ii) Protein levels of the λN fused RBP10 or 6 different 
fragments (F1-F6) of RBP10; expression was tetracycline induced (+ tet for 24h) and 
the fragments had C-terminus myc tags. Two independent clones (c1, c2) are 
shown. Aldolase or TR (trypanothione reductase) is the loading conrol; * is non-
specific band. B) Schematic representations of RBP10 fragments tested; the regions 
are colour coded and amino acid positions are shown on the full length RBP10 (all). 
C) The relative CAT mRNA and protein levels as determined by Northern blot and 
CAT assay respectively. Results of at least three replicates are shown; the error bar 
corresponds to the standard deviation. Cells without tethered protein served as 
control. The minimum fragment (F3) necessary for the repressor effect of RBP10 is 
highlighted in red. 
 
Using the same approach, six different fragments of RBP10 that were C-terminally 
myc tagged were tested. The aim was to map RBP10 region necessary for its 
inhibitory effect. RBP10 N-terminus (Figure 3.1 B, C; F2, F4) including the RRM 
motif failed to repress CAT expression. The low complexity C-terminal part (Figure 
3.1 A-ii; F3) was identified as the minimum region with the repressive effect (Figure 
3.1 B, C; F3). In this case, both CAT mRNA and protein levels were reduced by 
~80%. The repressor effect was lost when this region was deleted (Figure 3.1 B, C; 
F2), and fragment (Figure 3.1 B, C; F1) retaining the C-terminal part (highlighted in 
red, Figure 3.1 A, B; F3) as expected remains repressive. An attempt to narrow 
down further on the F3 fragment was not successful; when divided by half (Figure 
3.1 B, C; F6, F5), only F5 retained ~50% of the repressor effect while F6 had an 
opposing effect with a slightly positive effect on the CAT mRNA.  
 
3.2 Tethered RBP10 shifts reporter mRNA from the polysomes 
To understand in more detail how RBP10 acts as a repressor, the association of the 
CAT reporter mRNA with ribosomes was examined with and without tethered RBP10 
(C-terminus fragment; F3). After expression of λN-RBP10-F3, polysome fractionation 
was performed using extracts from the cells grown with (Figure 3.2 A-C) or without 
(Figure 3.2 D-E) tetracycline. Total RNA was isolated from each fraction and the 
distribution of both CAT and α-tubulin mRNAs analyzed by Northern blotting (Figure 
3.2 B, E). In absence of λN-RBP10-F3 the CAT mRNA co-migrated with the 
polysomes (Figure 3.2 B, C). Tethering of RBP10-F3 led to decreased levels of the 
CAT mRNA (Figure 3.2 E, F). In addition, <10% CAT mRNA was observed in the 
fractions containing translating polyribosomes; most of the quantifiable CAT mRNA 
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co-migrated with the fractions where normally ribosome subunits are found (Figure 
3.2 E, F). As a control, expression of λN-RBP10-F3 had no effect on either the 
amount or distribution of α tubulin mRNA (Figure 3.2 B, E). Therefore, RBP10 C-
terminus prevents translation initiation and promotes mRNA destruction. 
  
 
Figure 3.2 Translation repression after tethering RBP10 on reporter mRNA. (A & D) 
An OD254 trace of sucrose gradient (15-50%) of cells with or without λN-RBP10-F3. 
(B & E) Northern blot analysis of the CAT and tubulin mRNAs isolated from equal 
amounts of each fraction. One of the three replica blot used for quantification is 
shown. (C &F) Quantification of CAT and tubulin mRNAs from three replicates.   
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3.3 Identification of RBP10 interacting proteins by yeast-two hybrid 
RBP10 acts as a negative regulator when tethered to reporter mRNA. To test 
whether the inhibition of the reporter translation by RBP10 occurs via interaction with 
the translation factors, yeast-two hybrid assay were performed using a few selected 
translation factors (Figure 3.3). RBP10 failed to interact with EF1-, EF2, eRF1, 
eRF3, eIF-5A and eIF-2B in a pairwise assays (Figure 3.3 A). The expression of all 
the proteins was confirmed (Figure 3.3 B) apart from eRF1 which was undetectable.  
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Figure 3.3 Pairwise yeast two-hybrid screen between RBP10 and translation factors. 
A) Plates showing interactions between RBP10 as bait and the translation factors 
EF1 α, EF2, eRF1 eRF3, eIF5A, eIF2B as the prey. Cells diluted 1:10 or 1:100 were 
grown on medium and high stringency nutrient selection media. P53 and SV40 T-
antigen interaction served as positive control. B) Bait and prey proteins expression 
were detected using anti-myc and anti-HA antibodies respectively. 
 
 
3.3.1 High throughput yeast two-hybrid screen using RBP10 as bait   
To identify RBP10 interactors through an unbiased approach, yeast cells expressing 
RBP10 as bait were transformed with a prey library (prepared by Dr. Esteban Erben) 
generated from random genomic DNA fragments of T. brucei. ~1.5 x106 independent 
clones were obtained (genome coverage ~7 folds), with ~1x105 expected to contain 
in frame fusion proteins. This complexity was reduced after selection (Figure 3.3.1 A) 
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for positive interactions; ~1500 colonies survived on the high stringency plates. 50 
colonies were randomly selected, and after plasmid rescue the inserts were 
confirmed by Xho I digestion (Figure 3.3.1 B) followed by individual plasmid DNA 
sequencing. The rest of the colonies were pooled and prey plasmids DNA isolated. 
After plasmid specific PCR amplification, the complexity of the inserts detected as a 
smear on agarose gel (Figure 3.3.1 C) was analyzed by high throughput DNA 
sequencing. The inserts from the input library (9302 ORFs being represented) 
served as the control. 
 
 
 
Figure 3.3.1. Genome wide yeast two-hybrid screen with RBP10 as bait. A) Number 
of independent clones obtained before and after selection on quadruple drop out 
(QDO) plates. B) Inserts confirmation from the rescued prey plasmids by XhoI 
digest. The inserts (2.5% of the selected clones) were identified by Sanger DNA 
sequencing. Seven clones in duplicate are shown; the control is an empty prey 
plasmid. C) Distribution of the DNA smear after prey plasmid specific PCR of the 
pooled clones. The inserts were identified using high throughput DNA sequencing 
(NGS). 
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83 ORFs with at least 10 sequence reads and more than one fragment 
representation were obtained. All the candidates identified by individual sequencing 
were confirmed in the genome-wide approach. Since RBP10 negatively regulates 
reporter mRNA when tethered, repressor partners of RBP10 with more than one 
positive fragment and at least 5 sequence reads were considered. To qualify as a 
repressor, a cut-off of 1.7 fold was used according to [82, 83] datasets. Based on this 
criterion 25 potential partners were found (Table 1), 16 of these (Table 1 A) had 
more than one positive fragment; 9 more candidates (Table 1 B) that met two of the 
requirements but had only one positive fragment are also included. Among the 25 
potential partners of RBP10, 8 of them (Table 1 highlighted in grey) are expressed in 
bloodstream form trypanosomes and binds mRNAs in vivo [82]. Comparative 
analyses using datasets from other similar screens of MKT1, NOT2, and eIF4E-IP 
(4E-IP) helped to identify common partners. RBP10 came up in the 4E-IP dataset 
(Table 1 A, B) and interestingly, one 4E-IP fragment (Table 1 B) was found in the 
RBP10 screen. Also, the RNA binding proteins RBP9, DRBD7, ZC3H14 and one 
hypothetical protein (Tb927.10.10050) are co-shared between RBP10 and 4E-IP. 
Surprisingly, RBP10 interacts with itself since 7 positive fragments (Table 1 A) of 
RBP10 were identified.   
 
 
 
 
Table 1. Potential partners of RBP10 as identified by genome wide yeast two-hybrid 
screen. A) The list shows proteins with >5 reads that had at least two positive 
fragments and are known [82, 83] as negative regulators when tethered to a reporter 
mRNA; the ones that met two of these requirements (B) are included as well. A 1.7 
fold change cut-off for the tethering effect was considered for the studies done using 
either the short gun library [83] or a complete ORF library of selected proteins [82]. 
For the RBP10 two-hybrid screen, the numbers of positive fragments and the 
maximum number of reads are shown. Also in the table are the common partners 
identified in similar screens with 4E-IP, NOT2 and MKT1; only the maximum number 
of reads are shown. Highlighted in grey are those known to bind poly A mRNA in 
bloodstream form trypanosomes according to the findings from [82]. nd = no data; 
Y2H = yeast two hybrid 
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Table 1. A 
   
RBP10 Y2H Other Y2H screens 
Esteban 
et.al 2014 
Lueong et.al 2016 
Protein ID Annotation 
No. of  
positive 
fragments 
RBP10 
(max. 
reads) 
4E IP 
(max. 
reads) 
NOT2 
(max. 
reads) 
MKT1 
(max. 
reads) 
"Shotgun 
library" 
tethering 
effect 
"ORFeome 
library" 
tethering 
effect 
mRNA 
binder? 
(pvalue) 
Tb927.3.3940 DRBD11 15 6012 nd nd nd 3 6.2 yes (0) 
Tb927.8.2780 RBP10 7 1606 205 0 nd 2.6 2.5 yes (0) 
Tb927.4.400 DRBD7 5 232 227 0 nd 3.4 6.9 yes (0) 
Tb927.11.14220 
hypothetical 
protein 
2 31 nd nd nd 3.9 nd yes (0) 
Tb927.5.1580 ZC3H13 14 2340 nd nd nd 3.2 7.3 yes (0.01) 
Tb927.6.5010 
hypothetical 
protein 
7 1473 nd nd nd 5.6 8.4 yes (0.01) 
Tb927.8.910 
hypothetical 
protein 
21 7898 nd nd nd 3.9 6 
unclear 
(0.05) 
Tb927.10.10050 
hypothetical 
protein 
17 4960 1129 1 nd 2.1 nd no (0.1) 
Tb927.3.3060 
hypothetical 
protein 
5 150 nd nd nd 3.2 6 no (0.09) 
Tb927.7.2680 ZC3H22 17 10369 nd nd nd 2.7 4.9 nd 
Tb927.6.4720 ZC3H15 10 2234 nd nd nd 4.4 1.5 nd 
Tb927.1.1470 
hypothetical 
protein 
7 890 nd nd nd 3.9 1.5 nd 
Tb927.6.4050 ZC3H14 7 2044 897 0 3 nd 4.5 nd 
Tb927.7.5380 DRBD12 2 3201 nd nd nd 2.1 2.5 nd 
Tb927.9.13970 
hypothetical 
protein 
2 57 0 0 0 nd 6.7 nd 
Tb927.8.6080 
hypothetical 
protein 
2 245 nd nd nd 1.7 nd nd 
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Table 1. B 
 
 
Repressors, >10 reads but <2 positive fragments 
Protein ID Annotation 
 
RBP10 Y2H Other Y2H screens 
Esteban 
et.al 2014 
Lueong et.al 2016 
No. of  
positive 
fragments 
RBP10 
(max. 
reads) 
4E IP 
(max. 
reads) 
NOT2 
(max. 
reads) 
MKT1 
(max. 
reads) 
"Shotgun 
library" 
tethering 
effect 
"ORFeome 
library" 
tethering 
effect 
RNA 
binder? 
(pvalue) 
Tb927.10.5250 ZC3H32 1 29 0 0 120196 nd 3.2 yes (0) 
Tb927.9.11050 4E-IP 1 14 nd nd nd 4.49 17.2 yes (0.01) 
Tb927.11.12120 RBP9 1 34 1176 1 nd 10.52 4.6 
unclear 
(0.05) 
Tb927.3.1920 NOT5 1 340 nd nd nd 2.35 11.9 
unclear 
(0.05) 
Tb927.8.7820 
Hypothetical 
protein 
1 530 nd nd 71 2.31 nd no (0.06) 
Tb927.7.2980 
Hypothetical 
protein 
1 35 nd nd nd 1.79 0.3 nd 
Tb927.10.12020 
Hypothetical 
protein 
1 367 nd nd nd 1.72 0.8 nd 
Tb927.9.10280 ZC3H48 1 1693 0 0 1 nd 2.4 nd 
Tb927.9.9840 
lipoic acid 
containing carrier 
protein 
1 1232 nd nd nd 5.59 nd nd 
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3.4 Genome wide yeast two-hybrid data confirmation using complete ORFs 
Using full length RBP26, ZC3H22, DRBD12, Tb927.10.10050 and 4E-IP ORFs, the 
interaction with RBP10 was confirmed (Figures 3.4.1-2) by pairwise yeast two-
hybrid. A screen using SV40 T-antigen or Lamin as controls identified ZC3H22, 
DRBD12 and Tb927.10.10050 as auto activating only when used as baits. 
 
 
Figure 3.4.1 Confirmation of the genome wide yeast two-hybrid data using full-length 
prey inserts. A) Plates showing pairwise interactions of RBP10 as prey and RBP26, 
ZC3H22, Tb927.10.10050, DRBD12 as baits. As a negative control a screen using 
SV40 T-antigen (T) as prey is shown (lanes 2 & 4); the asterisk (*) highlights the auto 
activating baits. P53/T interaction served as positive control. The cells were selected 
on quadruple dropout medium (QDO); blue colonies highlight addition confirmation 
by alpha-galactosidase assay. B) Reciprocal interaction. As in (A), but using RBP10 
as bait. Screening using Lamin (lanes 2 & 4) as bait served as a negative control. 
 
 
The interaction between RBP10 and 4E-IP in the yeast two-hybrid (Figure 3.4.2) 
requires the C-terminal part of RBP10 (Figure 3.4.2 A, B; F3) that has the repressor 
effect. RBP10 fragment lacking the C-terminal region failed to interact with 4E-IP 
(Figure 3.4.2 A, B F2). Also, shown in Figure 3.4.2 A (last plate set) is the 
confirmation that RBP10 can self-interact as identified in the RBP10 genome wide 
two-hybrid screen (Table 1 A). 
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Figure 3.4.2 Interaction of RBP10 and eIF4E-IP in yeast. A) Plates showing pairwise 
interactions between eIF4E-IP and full length RBP10 or the two fragments of RBP10 
F3 and F2. RBP10 self-interaction is also shown. The cells were selected on 
quadruple dropout medium (QDO); blue colonies highlight addition confirmation by 
alpha-galactosidase assay. B) Schematic representation of the RBP10 fragments 
checked for interaction with eIF4E-IP. C) Controls to check for auto activating baits. 
P53 and SV40 T-antigen (T) interaction served as positive control. D) Bait and prey 
proteins expression were detected using anti-myc and anti-HA antibodies 
respectively. BD is yeast GAL4 DNA binding domain; AD is the Activation domain. 
 
3.5 RBP10, RBP26 and 4E-IP interactions in bloodstream form trypanosomes 
Having confirmed that RBP10 interacts with RBP26 and 4E-IP in yeast-two hybrid 
(Figure 3.4.1-2), I wanted to find out whether this is true as well in trypanosomes. No 
follow up studies of ZC3H22, DRBD12 and Tb927.10.10050 were done in 
trypanosomes because all were detected as auto activating the yeast two-hybrid 
system when used as baits (Figure 3.4.1 A). Furthermore, the biological relevance 
for the interactions between RBP10, ZC3H22 and DRBD12 is unclear because these 
two candidates are not expressed in bloodstream form trypanosomes. 
In case of RBP26, extracts from bloodstream form cells expressing in situ V5-RBP26 
and inducible RBP10-myc was used for co-immunoprecipitation with α-myc beads. 
The cell line expressing only V5-RBP26 was used as control (Figure 3.5.1 A; lanes 
1-3). After precipitating RBP10-myc, V5-RBP26 was not preferentially co-purified; 
only a very faint band was detected (Figure 3.5.1 A; lane 6). However, only half of 
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the eluate was loaded since both tagged proteins have similar sizes. V5-RBP26 did 
not bind non-specifically to the beads as observed in the control (Figure 3.5.1 A; lane 
3). Therefore, the co-purification depended on the presence of RBP10, however it is 
a very weak interaction. 
The reciprocal co-immunoprecipitation using α-V5 beads was also checked. After 
precipitating V5-RBP26, co-precipitation of RBP10-myc was observed, and again 
only a weak signal was detected (Figure 3.5.1 B; lane 3). Whether RBP10-myc 
bound to the beads non-specifically was not tested in this case. 
 
 
 
Figure 3.5.1 Interaction of RBP10 and RBP26 in bloodstream form trypanosomes. 
A) Co-immunoprecipitation with α-myc beads using extracts from cells expressing 
V5-RBP26, with (lanes 4-6) or without (lanes 1-3) additional expression of RBP10 
myc. The precipitated proteins were detected by Western blotting using anti-myc, 
and anti-V5 antibodies. Ponceau staining served as a loading control. I: input, Un: 
unbound (both 3% of the lysate) and E: eluate (50% of the boiled beads in sample 
buffer). B) Reciprocal co-immunoprecipitation using α-V5 beads. 
 
For 4E-IP, co-immunoprecipitation with α-myc beads was done using extracts from 
bloodstream form cells expressing in situ V5-RBP10 and inducible 4E-IP-myc 
(Figure 3.5.2 A; lanes 1-3). As control, the cell line expressing only V5-RBP10 was 
used (Figure 3.5.2 A; lanes 4-6). Precipitating 4E-IP-myc resulted in co-purification of 
V5-RBP10 (Figure 3.5.2 A; lane 3). Lack of substantial V5-RBP10 co-purification in 
the control (Figure 3.5.2 A; lanes 6) indicated that RBP10 pull-down depended on 
the presence of 4E-IP-myc; this confirms the yeast two-hybrid data using full length 
RBP10 (Figure 3.4.2 A). Next, to verify whether RBP10/4E-IP interaction in 
trypanosomes occurs via the C-terminal region of RBP10 as observed in the 
pairwise yeast two-hybrid (Figure 3.3.4 A), co-immunopreciptation with α-V5 beads 
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was done using extracts from bloodstream form cells expressing an inducible C-
terminus myc tagged RBP10 fragment (RBP10-F3-myc) and in situ V5-4E-IP (Figure 
3.5.2 B). Precipitating V5-4E-IP failed to co-precipitate the C-terminus RBP10 
fragment, since RBP10-F3-myc was not detected in the eluate fraction from cells 
extracts having both V5-4E-IP and RBP10-F3 fragment (Figure 3.5.2 B; lanes 1-3) 
as similarly observed in the control (Figure 3.5.2 B; lanes 4-6). Therefore, this part of 
two-hybrid data could not be confirmed in trypanosomes. 
 
 
Figure 3.5.2 Interactions of eIF4E-IP and RBP10 in bloodstream form 
trypanosomes. A) With full length RBP10. Co-immunoprecipitation with α-myc beads 
using extracts from cells expressing V5-RBP10, with (lanes 1-3) or without (lanes 4-
6) additional expression of eIF4E-IP-myc. The precipitated proteins were detected by 
Western blotting using anti-myc, anti-V5 and as control anti-trypanothione reductase 
(TR). I: input, Un: unbound (both 3% of the lysate) and E: eluate (100% of the boiled 
beads in sample buffer). B) With C-terminus RBP10 fragment (RBP10-F3-myc). Co-
immunoprecipitation with α-V5 beads using extracts from cells expressing RBP10-
F3-myc, with (lanes 1-3) or without (lanes 4-6) V5-eIF4E-IP. The loading and 
detection as in (A), but with aldolase as the loading control. 
 
3.6 RBP10 and 4E-IP interdependency in procyclic forms  
3.6.1 Independent dual induction system using Tet and IPTG in procyclic 
forms 
RBP10 when over expressed in procyclics is lethal [91]. To investigate whether the 
effects of RBP10 in procyclic forms is dependent on 4E-IP levels, 4E-IP expression 
was knocked down prior to RBP10-myc over expression. To do this, the expression 
of RBP10-myc and depletion of 4E-IP had to be done independently. This was 
achieved by using a dual induction system where RBP10-myc was IPTG induced 
while 4E-IP RNAi was induced using tetracycline.  
For the IPTG inducible system [154], transient expression of the CAT reporter in the 
procyclic forms was tested initially since the system is not routinely used in our lab. 
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The presence of two lac operators downstream of the rRNA promoter allowed IPTG 
inducible expression of the CAT protein from an episome (Figure 3.6.1 A-B); the 
cells constitutively expressed the lac repressor (LacR) and were grown in presence 
of 1 mM IPTG for 15 hours. The uninduced cells, cells lacking the lac repressor and 
the ones transfected with a reporter without the lac operator served as controls 
(Figure 3.6.1 A-B). This result was further confirmed using stable procyclic cells 
lines; unlike in the transient expression (Figure 3.6.1 B), leaky expression was 
observed with ~ 30% CAT activity detected in absence of IPTG for the most tightly 
regulated clone (Figure 3.6.1 C). 
 
Figure 3.6.1 IPTG inducible system in procyclic trypanosomes. A) Schematic 
representation of the CAT reporters used; i) IPTG inducible construct with 2 lac 
operators, ii) The control reporter. Both integrate at the silent rRNA locus, bears 
rRNA promoter and have a puromycin selection marker. B) IPTG induced (1 mM 
IPTG for 15h) transient CAT expression in procyclic cells constitutively expressing 
the lac repressor (+lacR); cells lacking the lac repressor (-lacR) served as control. 
CAT protein levels were measured using CAT assay. C) CAT expression in stable 
procyclic cell lines constitutively expressing the lac repressor (+lacR). CAT protein 
was induced for 24 hours using 1 mM IPTG and then quantified by CAT assay. 
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Figure 3.6.2 Independent dual induction of RBP10 expression and eIF4E-IP RNAi in 
procyclic cells. A) From (i-ii) schematic representation of the tet inducible stemloop 
construct targeting eIF4E-IP, and IPTG inducible RBP10-myc expression construct. 
(iii-v) the growth effect of over expressing RBP10 in the background of eIF4E-IP 
knockdown. Induction was through out for 4E-IP RNAi; from day 2 RBP10-myc was 
induced. The asterisk (*) highlights the data from the individual clones; the rest of the 
growth curves (controls) are the same for all the plots. Wild type procyclic cells with 
(Wt+laR) or without (Wt PC) lac repressor and the uninduced cells served as control. 
Data from three independent clones is shown. B) Western blot showing the 
expression of V5-eIF4E-IP and RBP10-myc using extracts from cells (clones 1-3) 
where 4E-IP was knockdown (from day 1-3) and RBP10-myc expression induced 
from day 2. C) Western blot showing expression of RBP10-myc and V5-eIF4E-IP in 
cells lacking stemloop construct against eIF4E-IP. 
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Independent induction of 4E-IP RNAi (Tet) and RBP10-myc (IPTG) expression in 
procyclic cells was possible as shown on Figure 3.6.2. In comparison to the wild type 
cells, expression of the lac repressor caused a mild growth defect (Figure 3.6.2 A-i). 
4E-IP RNAi was induced for two days prior to RBP10-myc expression. During the 
two days when cells were grown in absence of IPTG, leaky expression of RBP10-
myc was observed (Figure 3.6.2 B-C) resulting in poor cell growth (Figure 3.6.2. A). 
After IPTG addition on day two, RBP10-myc was strongly expressed and as 
expected resulted in a severe growth defect. No difference in terms of cell numbers 
was observed (Figure 3.6.2 A) for the cell lines where 4E-IP was knocked down prior 
to RBP10-myc expression. Because of the leaky expression of RBP10 and inefficient 
knockdown of 4E-IP, the conclusion from this experiment was not clear.   
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3.7 Tandem affinity purification of RBP10 
To corroborate the yeast two-hybrid data, tandem affinity purification (TAP) was 
performed. For this purpose one RBP10 gene was altered so as to encode a protein 
with TAP tag on the N-terminus (in situ tagging). The functionality of the tagged 
protein was confirmed by knocking out the other copy of RBP10 (Figure 3.7.1 A; 
lanes 2-6); the cells grew normally (Figure 3.7.1 B).  
 
 
Figure 3.7.1 Functional in situ TAP tagging of RBP10 in bloodstream forms. A) 
Western blot confirming the absence of untagged RBP10 (lanes 2-6) in five clones 
(c1-5) with both in situ N-TAP-RBP10 and RBP10 single knockout (SKO); * is a non 
specific band. B) Cumulative growth curve for one of the clones (c4) in comparison 
to wild type (Wt) cells. 
 
The purification was done three times with or without RNAse A treatment (Figure 
3.7.2 A, C). Cells expressing an inducible GFP with a C-terminal TAP tag served as 
the control (Figure 3.7.2 B, C). As expected, no signal was detected after the TEV 
protease cleavage (Figure 3.7.2 A, B; lane 3); the antibody used recognizes the 
protein A part of the TAP tag that remains bound to the IgG matrix after the 1st 
purification step. 
 
Figure 3.7.2 C shows a Coomassie stained gel of the eluates recovered after the 2nd 
purification step using calmodulin beads. In the GFP control, fewer proteins were 
visible and some of the patterns looked different from the rest. The samples were 
divided into two gel slices (numbered boxes in Figure 3.7.2 C) per sample and 
analyzed by mass spectrometry. 
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Figure 3.7.2 TAP purification in bloodstream trypanosomes. A) First step of the TAP 
purification with IgG sepharose beads using extracts from cells expressing N-TAP-
RBP10 only. Elution was done by TEV protease treatment of the beads. The TEV 
cleavage efficiency was analysed by western blotting using rabbit anti-PAP antibody. 
Ponceau staining served as loading control. I: input, Un: unbound (both 0.2% of the 
lysate) and E: eluate (1.5% of the TEV eluate). A representative blot is shown of the 
three replicates done with and without RNAse A treatment. B) As in (A), but using 
extracts from cells expressing inducible GFP-TAP that served as background 
control. C) Coomasie stained gel of the TAP elute after the 2nd purification step with 
calmodulin sepharose beads; samples treated with (lanes 3-4) or without (lanes 1-2, 
5) RNAse A. Gel slices shown in numbered boxes were analyzed by mass 
spectrometry. 
 
120 proteins with at least two peptides in at least two of the replicates were 
identified. Among those only six were unique to RBP10 purification (Figure 3.7.3, 
Table 2), the rest (95%) have been identified at least once in other purifications done 
with different RNA binding proteins. Relative to the GFP control, 21 proteins were 2-
fold enriched; their interaction with RBP10 was not dependent on RNA. Common 
contaminants such as ribosomal proteins and abundant metabolic enzymes were 
also identified. 
 61 
 
Figure 3.7.3 Proportion of unique proteins identified from RBP10 TAP purification 
 
Since RBP10 promotes mRNA destruction when tethered, proteins involved in 
mRNA degradation were considered (Table 2). CAF40 was the only one reproducibly 
detected. It was previously identified in five other purifications, two of them using 
ZC3H32 and DRBD18; similar to RBP10 both act as negative regulators when 
tethered to mRNA. Interestingly, DRBD18 was co-purified in RBP10 TAP purification 
although not unique; ZC3H32 came up in the RBP10 yeast two-hybrid screen (Table 
1 B) but only one fragment was detected.  
 
On Figure 3.5.2-A, 4E-IP co-purified RBP10, however, no 4E-IP peptides were 
detected after RBP10 TAP. Furthermore, none of the RBPs suggested to interact 
with RBP10 by yeast-two hybrid screen (Figure 3.4.1, Table 1) were detected. One 
possibility is that interaction with RBP10 was transient; hence the putative interactors 
of RBP10 failed to withstand the two-step TAP purification. Overall, the RBP10 TAP 
purification data did not overlap with the genome wide yeast two-hybrid dataset. 
However, some of these putative partners might be true. An alternative method for 
example proximity dependent biotin identification (BioID) could be used to confirm 
interaction in trypanosomes.  
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Table 2. Peptide numbers of unique proteins plus proteins linked to RNA metabolism that were reproducibly detected after RBP10 
TAP. Shown are the 3 replicates (R1-3) with or without RNase A treatment. The GFP-TAP data served as control. A comparison to 
RBP10 yeast two hybrid is shown plus the fold changes of how much the candidate’s fragments repressed a lethal gene in a 
tethering assay. nd = no data. 
Protein ID Annotation 
unique peptide counts 
average/cont
rol comparison to other studies 
RBP10 TAP 
(no RNAse) 
RBP10 TAP 
(+RNAse) 
GFP
TAP 
(con
trol) 
no 
Rnas
e/GFP
+1 
+  
Rna 
se/G
FP+
1 
No. of 
times 
previo-
usly 
seen  
RBP10 
yeast 
two-
hybrid 
Tethering 
effect 
R1 R2 R3 R1 R2 R3 
(Erben.et.a
l 2014) 
Tb927.10.4180 
TFIIF-stimulated CTD 
phosphatase, putative 
4 0 2 4 1 1 0 2 2 0 no 1.3 
Tb927.4.3400 
hypothetical protein, conserved, 
ARM repeat 
3 2 3 2 2 2 0 2.7 2 0 no 1.4 
Tb08.27P2.160 ESAG3 pseudogene 
 
0 2 2 2 3 3 0 1.3 2.7 0 no nd 
Tb05.5K5.150 
small GTP-binding protein, 
putative 
0 2 2 5 2 3 0 1.3 3.3 0 no nd 
Tb927.7.5480 
dihydrofolate reductase-
thymidylate synthase 
0 2 5 0 0 0 0 2.3 0 0 no 2.1 
Tb927.9.12890 
hypothetical protein, conserved, 
Atrophin-1 domain 
4 1 2 0 0 0 0 2.3 0 0 no 1.5 
Proteins associated with RNA metabolism 
Tb927.8.2780 RBP10 16 26 34 11 36 30 5 4.2 4.3 1 yes 2.6 
Tb927.11.14100 DRBD4 (PTB2) 
 
 
6 5 5 2 1 0 0 5.3 1 3 no 1.0 
Tb927.11.4460 ALBA1 3 2 2 3 2 3 0 2.3 2.7 4 no 0.5 
Tb927.11.510 UBP2 5 6 9 5 2 1 0 6.7 2.7 6 no nd 
Tb927.11.14090 DRBD18 6 6 6 5 1 0 2 2 0.7 7 no 1.8 
Tb927.9.13990 DRBD2 19 3 4 0 0 0 0 8.7 0 7 no 1.0 
Tb927.4.410 CAF40 3 3 5 4 5 4 1 1.8 2.2 5 no 1.0 
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3.8 RBP10 BioID in bloodstream form trypanosomes 
As an alternative approach to TAP purification, the proximity-dependent biotin 
identification method (BioID) was tested in bloodstream forms. To achieve this, 
RBP10 was in situ tagged on the N-terminus with the bacterial biotin ligase (BirA) 
and the construct was introduced into RBP10 single knockout cell line. Only a few 
clones grew; BirA-RBP10 fusion protein was detectable using anti-RBP10 antibody 
as shown on Figure 3.8-A. However, the untagged RBP10 protein was still present in 
those cells (slightly less than in the wild type, Figure 3.8-A) indicating either the 
fusion protein was not fully functional or it was a mixed cell population. 
To determine BirA-RBP10 ligase activity, cells were incubated with biotin for 24 
hours. A different protein Tb927.8.3850 in situ tagged with BirA, the untreated cells 
and wild type cells served as controls (Figure 3.8 B). As expected, a band 
corresponding to BirA-RBP10 was the strongest as detected by Western blotting 
using anti-streptavidin antibody (Figure 3.8 B, lanes 2,4). Furthermore, BirA-RBP10 
resulted to a unique pattern of biotinylated proteins (marked with an asterisk on 
Figure 3.8 B, lanes 2,4). This highlights potential interacting partners of RBP10 since 
none was observed in the controls (Figure 3.8 B). Because of time limitation the 
identity of the proteins by mass spectroscopy was not done in this study. 
 
Figure 3.8 N terminus in-situ tagging of RBP10 with BirA in bloodstream form 
trypanosomes. A) Expression of BirA-RBP10 in cells with a single knockout of 
RBP10. The fusion protein (~69 kDA) and the untagged RBP10 (~32 kDa) were 
detected using anti-RBP10 antibody. The non-specific (NS) band served as the 
loading control. Cells were incubated for 24 hours with biotin (lanes 2, 4) to test the 
ligase activity of the fusion protein. Data from two independent clones is shown. B) 
Detection of biotinylated proteins using anti-streptavidin antibody. Wild type cells 
(lanes 5, 6) and a different BirA tagged protein (Tb927.8.3850; lanes 7, 8) served as 
controls. The asterisk (*) highlights RBP10 biotinylated proteins that may be 
increased with RBP10-BirA.  
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3.9 Transcriptome wide effects of RBP10 manipulation in T. brucei  
3.9.1 Time point selection for RNA sequencing 
To determine the effects of RBP10 on mRNA abundance and/or translation, I 
examined transcriptome changes after RBP10 RNAi in bloodstream forms or RBP10 
over expression in procyclic forms. In addition, how such changes affected the 
association of mRNAs with the polyribosomes was investigated. In both experiments 
time course studies were done to examine RBP10 changes relative to growth 
inhibition. Between 14-16 hours post RBP10 RNAi, no growth inhibition was 
observed and less than 10% RBP10 protein was detectable (Figure 3.9.1.1).  
 
 
 
Figure 3.9.1.1 Time course RNAi against RBP10. Western blot using cell extracts 
taken at different time points after RBP10 RNAi in bloodstream form trypanosomes. 
RBP10 was detected using anti-RBP10 antibody. The protein quantification relative 
to the minus RNAi control is shown below the blot. * is non specific band used as the 
loading control. 
 
In case of RBP10-myc over expression (Figure 3.9.1.2) in procyclics, expression for 
24 hours resulted to a moderate decrease in global translation (Figure 3.9.1.2 A, B). 
Consequently, earlier time points were checked. RBP10-myc was detectable two 
hours post induction; within six hours it was strongly expressed (Figure 3.9.1.2 C, D). 
Global translation (Figure 3.9.1.2 B) and growth were unaffected after 4-6 hours of 
RBP10-myc expression (Figure 3.9.1.2 C, D).  
 
Based on these time courses, 15 hours of RBP10 RNAi in bloodstream forms (Figure 
3.9.1.1) and 6 hours of RBP10-myc expression in procyclic forms (Figure 3.9.1.2) 
were selected for transcriptome analyses.  
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Figure 3.9.1.2 Time course expression of RBP10 in procyclic cells. (A & B) Global 
translation at different time points after RBP10-myc expression as detected using 35S 
labelling. (C & D) Levels of RBP10-myc after 2, 4, and 6 hours of expression as 
detected by Western blotting using anti RBP10 (C) or anti myc (D) antibody. 
 
After 15 hours of RBP10 RNAi in bloodstream forms or 6 hours of RBP10-myc 
expression in procyclic forms, the cell extracts were subjected to polysome 
fractionation; in both cases uninduced cells served as control. RNAseq was used to 
quantify the mRNA changes from two pools of the polysome fractions, i) lighter 
fractions including monosomes, ii) denser fractions with at least two ribosomes; 
shown on Figure 3.9.1.3-4 (A). Analyses of the input samples (without fractionation) 
was used to monitor changes in mRNA abundance. 
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Figure 3.9.1.3 Polysome profiling in bloodstream form trypanosomes depleted of 
RBP10. A) A representative polysome profile obtained using extracts from cells with 
or without RBP10 depletion by RNAi for 15 hours. The two mRNA pools analyzed by 
RNA sequencing after rRNA depletion are shown. The experiment was done in 
duplicates and cells lacking RNAi served as the control. B) Northern blot using 1/20th 
of the RNA isolated from the pooled (b, c) samples; for the input (a) 2 μg of the RNA 
was loaded. The total mRNA was detected by hybridization of the blot with a splice 
leader probe. C) Quantifications of the splice leader signal obtained from (B). The 
Northern blot was repeated twice.* = non specific band. 
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Figure 3.9.1.4 Polysome profiling in procyclic form trypanosomes over expressing 
RBP10. A) A representative polysome profile obtained using extracts from cells with 
or without RBP10 expression for 6 hours. The two mRNA pools analyzed by RNA 
sequencing after rRNA depletion are highlighted. For each condition two biological 
replicates were used. B) Northern blot using 1/20th of the RNA isolated from the 
pooled (b, c) samples; for the input (a) 2 μg of the RNA was loaded. The total mRNA 
was detected by hybridization of the blot with a splice leader probe. C) 
Quantifications of the splice leader signal obtained from (B). The Northern blot was 
repeated twice. * = non specific band. 
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3.9.2 Transcriptome changes after RBP10 depletion for 15 hours  
Both the DESeq2 package and RPM (reads per million) estimations were used for 
the RNAseq data analyses. Figure 3.9.2.1-A shows the reproducibility between 
replicates of the input samples. Clustering was strong for the samples without 
RBP10 RNAi in comparison to the ones where RBP10 was depleted, nonetheless 
there was 79% variation between the conditions as determined by principal 
component analysis (PCA). After normalization based on DESeq2 algorithm, similar 
distributions of the read counts was observed (Figure 3.9.2.1 B), confirming the 
normalization was successful.  
 
 
Figure 3.9.2.1 Quality check of the RNAseq data. A) PCA plot of the input samples 
with and without RBP10 RNAi. B) Read counts distribution shown using a density 
plot.  
 
 
DESeq2 identified 420 mRNAs as being significantly (p<0.05) affected after RBP10 
depletion (highlighted in red in Figure 3.9.2.2). Considering those with at least ~1.5 
fold change (those above/below the dotted line in Figure 3.9.2.2), 103 mRNAs were 
up regulated while 103 mRNAs got down regulated. 
Most of the mRNAs down regulated are more abundant in bloodstream forms (Figure 
3.9.2.3); ~10% of the mRNAs that showed reduced expression encode proteins 
involved in glucose metabolism; the main source of ATP in bloodstream form 
trypanosomes. Apart from RBP10, five other regulatory proteins PUF11, ZC3H31, 
ZC3H46, DRBD5 and RBP9 were significantly reduced possibly leading to 
combinatorial effects. 
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Figure 3.9.2.2 mRNA changes (input samples) after RBP10 RNAi for 15 hours. The 
MA plot highlights the fold changes relative to the cells without RBP10 RNAi 
(uninduced). mRNAs that showed differential expression (p<0.05) are highlighted in 
red; the two dashed lines show the mRNAs subsets with at least 1.5 fold change. 
 
 
The majority of the mRNAs up-regulated were procyclic form specific (Figure 
3.9.2.3). The transition from bloodstream to procyclic form involves changing of the 
surface coat proteins, mitochondrion activation and switching of the energy 
metabolism from glycolysis to oxidative phosphorylation. 34% of the mRNAs that 
showed increased expression encode proteins involved in different mitochondrion- 
specific pathways. Among these ~14% code for proteins involved in the citric acid 
cycle. The mRNA coding for the surface coat protein EP1 was 4x up-regulated. 
ZC3H22 and ZC3H20 were the only RNA binding proteins significantly up-regulated 
after RBP10 depletion for 15 hours.  
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Figure 3.9.2.3 mRNA changes after RBP10 RNAi. A) A clustered heatmap showing 
the relationship between RBP10 RNAi effects and development regulation; the 
dataset for developmental regulation is from [144], comparing bloodstream (BS) 
versus the procyclic forms (PC). Uninduced cells served as control. 
 
Next, RBP10 effect on translation was investigated by comparing the changes seen 
on total mRNA (input samples) versus polysome loading (proportion of mRNAs 
associating with polyribosomes). In this case, RPM (reads per million) for each gene 
were calculated. For the polysome fractions pools, RPM values were calculated after 
normalizing for the amounts of starting RNA using the signal from the splice leader 
(Figure 3.9.1.3 B-C). To estimate the proportion of the mRNAs associating with the 
polyribosomes, individual gene RPM was divided with the sum of the amount found 
in the two pools of mRNA sequenced after sucrose density fractionation (Figure 
3.6.1.3 A); comparison were made between samples with or without RBP10 RNAi. 
As expected, RBP10 mRNA showed reduced abundance as well as decreased 
polyribosome association (Figure 3.9.2.4). PUF11 is the only other RNA binding 
protein that had a similar pattern. 53 mRNAs showed increased (at least 1.5x) 
association (violet-red and cyan coloured on Figure 3.9.2.4) with the polyribosomes 
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when RBP10 was depleted. Among those 8 had both increased (at least 1.5x) 
polysome loading and abundance (coloured in cyan on Figure 3.9.2.4). Overall, there 
was only a very slight correlation (R=0.38) between the effects of RBP10 depletion 
on mRNA abundance and on polysome loading.  
 
 
 
Figure 3.9.2.4 The relationship between the effects of RBP10 depletion on the 
mRNA abundance and polysome loading (proportion of mRNAs associating with 
polyribosomes). mRNAs that moved (at least 1.5 fold) to the polysomes are 
highlighted in two colours, i) violet-red are those that showed increased polysome 
association but less changes in abundance. ii) In cyan had both changes; the names 
of a few selected mRNAs that are developmentally regulated are shown. The linear 
regression line (in black) plus the 95% confidence limits (in grey) of the scatter plot 
are included.  
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3.9.3 Transcriptome changes after RBP10 expression for 6 hours in procyclic 
cells  
The polysome RNA seq data was analyzed as described in section 3.9.2. PCA plot 
(Figure 3.9.3.1 A) was made to check variation between the replicates. Figure 
3.9.3.1 B highlights the success of the normalization procedure using DESeq2 
algorithm.  
 
 
Figure 3.9.3.1 Quality check of the RNAseq data. A) PCA plot of the input samples 
with and without RBP10 expression. B) Read counts distribution shown using a 
density plot. 
 
Upon RBP10 expression for 6 hours in procyclic cells, 453 mRNAs were significantly 
affected (p<0.05) as determined using DESeq2. Considering those with at least ~1.5 
fold change (those above/below the dotted line in Figure 3.9.3.2), 29 mRNAs were 
up regulated while 48 mRNAs got down regulated.  
RBP10 mRNA was 18x up regulated (Figure 3.9.3.2); within those up regulated, 16 
are more abundant in the bloodstream forms (Figure 3.9.3.3). Although it was not a 
perfect inverse of what was observed after RBP10 RNAi in bloodstream form, 5 
mRNAs up regulated after RBP10 expression were at least 1.5 fold down regulated 
after RBP10 RNAi. Three encodes enzymes involved in the glycolytic pathway, one 
encodes RNA binding protein DRBD5 and the other one codes for a phosphatase 
that is bloodstream form specific.  
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Figure 3.9.3.2 mRNA changes (input samples) after RBP10 expression for 6 hours 
in procyclic cells. The MA plot highlights the fold changes relative to the cells without 
RBP10-myc (uninduced). mRNAs that showed differential expression (p<0.05) are 
highlighted in red; the two dashed lines show the mRNAs subsets with at least 1.5 
fold change. 
 
 
RBP10 expression for 6 hours resulted to a moderate effect on the transcriptome; 
mRNAs significantly down regulated formed the majority (Figure 3.9.2-3). Within the 
48 mRNAs that met the cut off criteria (p<0.05 and 1.5x down), 26 are more 
abundant in the procyclic trypanosomes. Interestingly, 11 of those showed opposite 
effects when RBP10 was depleted in bloodstream forms. EP1 mRNA was 4 times up 
regulated after RBP10 RNAi in bloodstream form; upon expression of RBP10 in 
procyclics EP mRNA was 1.6 fold decreased. In addition trans sialidase mRNA 
which encodes another membrane protein showed similar pattern. In terms of 
regulatory factors, ZC3H22 mRNA was affected after RBP10 depletion however 
expression of RBP10 in procyclics resulted to only 1.4 fold decrease of the ZC3H22 
mRNA. 
Seven chaperone mRNAs more abundant in procyclic forms were significantly down 
regulated. The procyclic form specific phoshoglycerate kinase B (PGK-B) was 1.6 
fold down regulated after RBP10 expression in procyclic cells. 
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Figure 3.9.3.3 mRNA changes after RBP10-myc expression in procyclic cells. A) A 
clustered heatmap showing the relationship between effects of RBP10-myc 
expression and development regulation; the dataset for developmental regulation is 
from [144], comparing bloodstream (BS) versus the procyclic forms.  
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3.10 RBP10 mRNA targets 
Changes in RBP10 levels significantly up-regulate or down-regulate many mRNAs 
(sections 3.9.2-3.9.3). But, does RBP10 bind all of these mRNAs? To identify 
mRNAs directly bound by RBP10, a cell line with functional N-terminally TAP tagged 
RBP10 was used. The mRNP complexes were preserved by UV cross-linking. After 
precipitation using IgG-agarose beads, elution was done using TEV cleavage and 
the proteins digested with proteinase K. The co-purified (bound) RNA was isolated 
and identified by RNA seq. To determine the enrichment, the unbound fraction 
served as the control. The replicates from both eluate and unbound fractions were 
highly reproducible as determined by PCA plot (Figure 3.10.1 A).  
 
 
 
Figure 3.10.1 Quality check of the RNAseq data. A) PCA plot showing replicates of 
the eluate and unbound samples after TAP-RBP10 RNA pull downs. B) Read counts 
distribution shown using a density plot. 
 
About 300 mRNAs (Figure 3.10.2 A) were at least 3 fold enriched on average when 
comparing bound versus the unbound. mRNAs down-regulated (>1.5x) after RBP10 
RNAi were strongly underrepresented in the bound fraction. Interestingly, 39% (40 
out of 103) of the mRNAs up-regulated (>1.5x) after RBP10 RNAi (15h) were 
significantly enriched in the RNA IP data set (Fig. 3.10.2 A). This data set highlights 
mRNAs targets bound and regulated by RBP10 in bloodstream form. On the 
contrary, <1% (3 out of 103) were both bound and down regulated (1.5x) after 
RBP10 RNAi; one of them being the mRNA encoding RBP10.   
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Figure 3.10.2 mRNAs bound and regulated by RBP10. A) A Venn diagram 
highlighting mRNAs bound and regulated by RBP10. The RNAi data set is the same 
as in Figure 3.9.2.3. mRNA was considered bound if it had at least 3 fold enrichment 
(bound/unbound). Fischer exact test values, calculated for the overlap in the 
datasets, are in blue. C) The motif enriched in the 3’ UTRs of mRNAs strongly bound 
by RBP10; the DREME tool (http://meme-suite.org/tools/meme) was used for the 
motif search. 
 
To narrow down to the potential direct targets of RBP10, I considered the fact that 
RBP10 acts as a negative regulator when attached to a reporter mRNA (Figure 3.1). 
Therefore, I looked for the mRNAs that are i) bound by RBP10 ii) up-regulated after 
RBP10 RNAi iii) developmentally regulated (highly unstable in bloodstream forms). 
Using these filters, 31 mRNAs (Figure 3.10.2 and Table 3) were identified as direct 
target of RBP10 and possibly are repressed by RBP10. Interesting candidates within 
this list included mRNAs encoding surface protein EP procyclin, two RNA binding 
proteins ZC3H20 & ZC3H22, three different cytochrome complex proteins, four 
enzymes required for the procyclic form energy metabolism, two protein kinase, one 
phosphatase and several other proteins of unknown function (full list is shown on 
Table 3). Next, the 3' UTRs of the enriched transcripts were analysed for motifs 
using the motif-based sequence analysis tool (DREME). We used 3' UTRs of the 
<0.7x bound mRNAs as background control. The motif UAUUUUUU was highly 
enriched (E=3.2 e-79) in the bound fraction (Figure 3.10.2 B). Convincingly, all the 
31 high confidence targets of RBP10 contained at least one of the identified motif 
(Table 3).  
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Table 3 High confidence mRNA targets of RBP10. BS=bloodstream form, 
PC=procyclic form, KD=knockdown 
Gene ID Annotation 
BS  
KD 
PC+  
RBP1
0 
PC/
BS 
  
Repress
or effect 
UA(A6) 
motif 
count 
Membrane 
      Tb927.10.10250 EP2 procyclin (EP2) 3.7 0.6 50 n/a 3 
Tb927.7.6850 Trans-sialidase (TbTS) 2.2 0.6 2.6 n/a 4 
Tb927.8.7340 Trans-sialidase 1.6 0.4 3.3 n/a 3 
Tb927.4.3500 Amastin-like protein 1.6 0.9 10 n/a 1 
Mitochondrion       
Tb927.10.2350 Pyruvate dehydrogenase 
complex 
1.7 0.8 4.8 n/a 1 
Tb927.9.5900 Glutamate dehydrogenase 1.8 1.1 7.1 n/a 4 
Tb927.10.4280 Complex III cyctochrome 
bc1 
1.8 0.7 25 n/a 2 
Tb927.11.15550 NADH-cytochrome b5 
reductase 
1.5 0.9 2.9 n/a 1 
Tb927.5.3040 Cytochrome c Oxidase 
complex 
1.6 0.9 2.5 n/a 1 
Tb927.7.210 Proline dehydrogenase 1.8 1.0 7.7 n/a 3 
Tb927.9.4310 Tricarboxylate carrier 1.5 1.3 4.3 n/a 1 
Regulation       
Tb927.2.4200 Protein kinase 1.5 0.8 2.3 n/a 4 
Tb927.11.15010 NEK21 protein kinase  1.9 0.9 1.8 n/a 4 
Tb927.10.8050 Protein phosphatase 1.9 0.8 3.5 n/a 2 
Tb927.7.2680 ZC3H22 1.6 0.7 2.4 4.9 7 
Tb927.7.2660 ZC3H20 1.5 1.1 3.5 n/a 2 
Other       
Tb927.9.7470 Purine nucleoside  
transporter NT10 
2.2 0.7 12.5 n/a 1 
Tb927.10.7700 ABC transporter 1.6 0.7 2.9 n/a 2 
Tb927.8.7730 Dihydroceramide synthase 1.7 0.5 2.3 n/a 2 
Tb927.10.10770 Generative cell specific 1  1.6 0.6 2.1 n/a 2 
Tb927.4.2410 Haloacid dehalogenase-
like hydrolase 
1.5 1.4 1.9 n/a 1 
Tb927.10.3300 Unknown function 1.5 0.8 3.3 n/a 1 
Tb927.4.4940 Unknown function 1.8 0.8 4.4 n/a 3 
Tb927.7.5550 Unknown function 1.5 0.7 2.8 n/a 2 
Tb927.6.3880 Unknown function 2.5 0.6 2.6 n/a 6 
Tb927.10.11630 Unknown function 1.6 0.9 2.2 0.6 2 
Tb927.1.1470 Unknown function 1.5 0.9 2.6 1.5 5 
Tb927.11.1830 Unknown function 1.8 0.9 2.2 n/a 2 
Tb927.9.1520 Unknown function 1.7 0.8 3.5 n/a 1 
Tb927.9.13200 Unknown function 1.7 0.6 12.5 n/a 2 
Tb927.11.16300 Unknown function 1.5 0.9 6.7 n/a 1 
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3.11 RBP10 binding to EP 3’ UTR  
To validate the RNA IP data, EP 3' UTR was selected. It is already known [155-158] 
that in the bloodstream forms the EP procyclin mRNA is not translated and is highly 
unstable (half life <5 mins). Interestingly, two repeats of the UAUUUUUU sequence 
are present in the 26mer instability element on the EP 3' UTR. The 26mer element is 
responsible for the extreme instability and translation repression of EP mRNA in 
bloodstream form [155, 158], and is known to be single stranded in vivo [156]. To 
test whether RBP10 binds EP mRNA via this element, RNA pull-down was 
performed using anti-RBP10 antibody in cells constitutively expressing CAT reporter 
mRNA containing either full length EP 3' UTR (CAT-EP) or a deletion version lacking 
the 26mer (CAT-EPΔ26) instability element (Figure 3.11.1 A, B). The cDNA prepared 
from the co-purified RNA or the unbound fraction was used in a semi-quantitative 
RT-PCR (Figure 3.11.1 C), and a region on the ORF of the CAT reporter and tubulin 
mRNAs was amplified. The CAT PCR product was detected only in the sample with 
the full length EP 3' UTR. On the other hand, no product was detectable by PCR 
when the motif was deleted (Figure 3.11.1 C), confirming the regulatory 26mer 
element is required for RBP10 binding the EP 3' UTR.  
 
Figure 3.11.1 The 26mer instability element in the EP1 3’ UTR is required for RBP10 
binding. A) Schematic representation of the CAT reporter used. B) Western blot 
showing RBP10 protein was equally pulled down after immunoprecipitation using 
agarose beads coupled with anti-RBP10 antibody; I = input (3%); Un = unbound 
(3%); E = eluate (1%). C) RT-PCR to detect CAT and tubulin (TUB) mRNAs after 
RBP10 immunoprecipitation. The cells used expressed CAT reporter with either full 
length EP or EPΔ26 3' UTR. For tubulin only a very faint band was detected in the 
eluate. * = non specific band used as the loading control.  
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Depletion of RBP10 by RNAi for 17 or 24 hours successfully rescued the translation 
repression conferred by the presence of the 26mer instability element (Figure 
3.11.2). Increased expression was only seen for the CAT-EP1 reporter but not for 
mutant (CAT-EPΔ26) version. However, a decline in the CAT protein after 24 hours 
of RBP10 RNAi was observed in the cells with CAT-EPΔ26 3' UTR; possibly due to 
growth inhibition.  
These results demonstrate that RBP10 binds the EP 3’-UTR via the 26mer 
sequence, and the element is required for regulation by RBP10 of a reporter mRNA 
bearing the EP1 3’-UTR. The data strongly support UA(U)6 as the binding motif for 
RBP10, however direct binding to the motif will need to be confirmed using other 
methods such as electrophoretic mobility shift assay (EMSA).  
 
 
 
Figure 3.11.2 Regulation by the EP1 3’ UTR is dependent on the presence of 
RBP10. A) CAT activity was measured in the same cell lines as in Figure 3.11.1 but 
with an inducible RNAi construct targeting RBP10. Depletion of RBP10 for 17h or 
24h increased the expression of the CAT reporter (CAT-EP1) containing the two 
UAUUUUUU repeat sequence. B) RBP10 levels after 17h and 24h knockdown as 
detected by Western blot using anti-RBP10 antibody; data from three independent 
clones is shown.  
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3.12 RBP10 and trypanosome differentiation  
3.12.1 Bloodstream to procyclic form conversion 
Bloodstream-to-procyclic form differentiation involves an intermediate stage known 
as the stumpy form. In culture, synchronised stumpy form cells differentiate 
efficiently to procyclic forms after incubation with 6mM cis-aconitate at 270C [123, 
159].  
Given that RBP10 binds to and inhibits expression of procyclic form specific mRNAs 
in bloodstream forms, I wanted to determine whether depletion of RBP10 
accelerates differentiation towards procyclic forms in absence of external stimuli 
such as cis-aconitate. To test this, a tetracycline inducible stem-loop construct 
targeting RBP10 was introduced in pleomorphic bloodstream form trypanosomes. 
After 17 hours of RNAi induction RBP10 protein was strongly reduced, the cell 
density was unaffected and the differentiation marker PIP39 was strongly up 
regulated while EP procyclin was undetectable (Figure 3.12.1.1 A). Prolonged 
induction of RBP10 RNAi inhibited growth (Figure 3.12.1 A) with PIP39 levels 
increasing over time (Figure 3.12.1.1 B).  
In vitro differentiation to procyclic forms requires a change in media and temperature 
reduction. Therefore, after 17 hours of RBP10 RNAi, cells were transferred into 
procyclic form media and incubated at 27oC (Figure 3.12.1.1 C). As positive control 
for differentiation, the growth arrested stumpy cells couldn’t be used since the RNAi 
was done using log phase bloodstream form cell. Consequently, high-density wild 
type EATRO1125 cells were treated for 17 hours with 6 mM cis-aconitate at 270C 
before transfer to procyclic medium without cis-aconitate. The untreated and the 
minus RNAi cells died after 3 days (Figure 3.12.1.1 C). Surprisingly, the RNAi cells 
survived and showed similar differentiation kinetics to the cis-aconitate treated 
control (Figure 3.12.1.1 C); with expression of the procyclic form surface coat protein 
EP within 6 hours after the temperature shift and both PIP39 and EP proteins 
reaching wild type levels after 3 days when the cell number started to increase 
(Figure 3.12.1.1 C, D). The cell population treated with cis-aconitate, however, 
retained some RBP10 expression until day two (Figure 3.12.1.1 C, D); this could be 
a result of a few bloodstream form cells persisting, then dying after three days. 
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To confirm that the cells were bona fide procyclic forms, the morphology of the cells 
was further analysed using indirect immunofluorescence (a blind analysis was done; 
where Prof. Christine Clayton did the quantification for all the images that I 
recorded). We looked for morphological changes consistent with differentiation from 
bloodstream to the procyclic forms; such as the surface coat exchange from VSG to 
EP/GPEET, expression of PAD1 (stumpy form marker), and kinetoplast repositioning 
from posterior end in bloodstream to a midway position between the nucleus and the 
posterior end in procyclic forms. After RBP10 RNAi for 17 hours, cells retained the 
long slender morphology, and PAD1, EP1 and GPEET could not be detected. 
However, upon incubation in MEM medium at 270C for three days, more than 80% of 
the cells became GPEET positive and their kinetoplast was repositioned at a midway 
position between the nucleus and the posterior end; characteristic of procyclic cells 
(Figure 3.12.1.2 A, C). Similar results were obtained for the positive control cells 
induced to differentiate using cis-aconitate (Figure 3.12.1.2 A, D).  
 
Figure 3.12.1.1 RBP10 depletion primed bloodstream form cells to differentiate to 
procyclic forms. A) Growth curve after RBP10 RNAi. B) Expression of RBP10, PIP39 
and EP1 for samples from (A). C) Cell densities after transfer to procyclic medium at 
27oC for cells transformed by 17 hours RBP10 RNAi (+RNAi) or 6 mM cis-aconitate 
(+CA): the untreated ones (WT-CA & -RNAi-CA) served as negative control. D) 
Protein expression from (C). (Figure modified by C. Clayton) 
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In bloodstream forms the kinetoplast is very near the posterior cell tip, so that the 
ratio of distance from the posterior end to the kinetoplast (P-K) and the distance from 
kinetoplast to the nucleus (K-N) is much smaller than in procyclic forms. We used 
this ratio (P-K/K-N) to compare the kinetoplast repositioning after differentiation 
mediated by RBP10 RNAi or cis-aconitate. The cells generated by RBP10 RNAi or 
cis-aconitate showed a similar pattern of kinetoplast positioning; this was much 
closer to that of established procyclic form culture, and it differed significantly from 
the starting bloodstream form culture where the ratio was much smaller (Figure 
3.12.1.2 B). In both RBP10 RNAi and cis-aconitate converted cells, ~10% of the cells 
retained the slender morphology and some were GPEET negative (Figure 3.12.1.2 
C, D). 
 
Based on these results, we suggest RBP10 is a major negative regulator of 
differentiation in bloodstream forms. It acts by repressing mRNAs normally enriched 
in the procyclic forms. Loss of this regulation is lethal and gives rise to cells primed 
to differentiate from bloodstream to procyclic forms; this occurs in absence of cis-
aconitate but is dependent on temperature reduction to 270C.  
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Figure 3.12.1.2 RBP10 depleted bloodstream form cells survive after transfer to 
MEM medium at 27oC. A) Surface coat exchange from VSG to GPEET after RBP10 
RNAi for 17h or cis-aconitate treatment then transfer to MEM medium at 27oC for 3 
days. B) Kinetoplast repositioning estimated as a ratio of the distance from the 
posterior end to the kinetoplast (P-K) and the distance from kinetoplast to the 
nucleus (K-N); analysis was done for cells depleted for RBP10 for 17h or cis-
aconitate treated, also for cells taken after day 3 and 6 in MEM medium at 27oC. C-
D) The distribution of the estimated ratio (P-K/K-N) with the percentage of the 
GPEET positive cells included. BS=bloodstream; BS+Ri=BS after 17h of RBP10 
RNAi; BS+CA= BS after 17h cis-aconitate treatment. (Figure B,C,D were made by C. 
Clayton) 
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3.12.2  Procyclic to bloodstream form conversion 
Depletion of RBP10 primes the bloodstream forms cells to differentiate to procyclic 
forms. I then asked, could over expression of RBP10 in procyclic forms convert the 
cells to bloodstream forms? To test this, RBP10-myc was ectopically expressed in a 
procyclic cell line derived from EATRO1125 strain. As expected, prolonged 
expression of RBP10 significantly inhibited cell growth, and caused reduction of EP 
procyclin (Figure 3.12.2.1 A, B). After 2 days the cells had increased expression of 
bloodstream form markers hnRNPH, TAO and native RBP10 (Figure 3.12.2.1 B, C). 
VSG mRNA was detected within 24 hours (Figure 3.12.2.1 C) and VSG protein after 
2 days (Figure 3.12.2.2).  
 
 
Figure 3.12.2.1 RBP10 expression triggers procyclic forms to differentiate to 
bloodstream forms. A) Left chart: Growth curve after RBP10-myc induction; Right 
chart: Cell densities after transfer to bloodstream medium at 37oC; the samples 
taken are highlighted on the left chart; no tetracycline was added once the transfer 
was made. Uninduced (-tetRBP10-myc) and wild type (WT) cells served as controls. 
B-C: Expression of EP1, TAO, hnRNPH, PIP39 and native RBP10 after over 
expression of RBP10 for 4 days in procyclic cells; detection of VSG mRNAs by RT-
PCR is also shown(C). (Figure modified by C. Clayton) 
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FACs analysis confirmed half of the cells had reduced or no EP procyclin and 16% 
cross-reacted with anti-VSG117 (Figure 3.12.2.2 A, C); some of the cells had already 
acquired bloodstream form morphology (Figure 3.12.2.2 B; Figure 3.12.2.3 A). 
Interestingly, after 2 days of RBP10 expression and transfer to 37oC in HMI-9 
medium some cells survived and started to divide as bloodstream forms (Figure 
3.12.2.1 A right chart); with >60% of the cells being VSG positive after six days as 
determined by immunofluorescence using anti-VSG117 (Figure 3.12.2.3 B). The cell 
lacking RBP10 as well as the wild type procyclic forms died after 3 days confirming 
there was no prior bloodstream form cells in the population. 
 
 
Figure 3.12.2.2 Over expression of RBP10 in procyclics cells leads to loss of surface 
coat procyclins. A) Percentage of cells expressing EP1, GPEET and VSG117 at the 
surface as determined by FACs analysis. Values represent means from four 
biological replicates. B) Image showing a mixed cell population after RBP10 
expression for two days; PC=procyclic form cell with reduced EP procyclin, BS= 
bloodstream form cell positive for VSG117, * unusual cell with bloodstream form like 
morphology. C) Representative FACs plots showing expression levels of EP, GPEET 
and VSG117. (Figure modified by C. Clayton) 
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Figure 3.12.2.3 Some procyclic cells expressing RBP10 converts to bloodstream 
forms. A) Procyclic cells with or without RBP10 expression single stained with anti-
VSG117. B) Proliferating bloodstream form cells generated by over expression of 
RBP10 then transfer to HMI-9 medium at 370C for six days. 
 
Since anti-VSG117 failed to stain some of the cells that had acquired bloodstream 
form morphology, transmission electron microscopy (TEM) was used to further 
confirm surface coat exchange from the thin EP procyclin coat to a very dense VSG 
coat. Similar to IFA and FACS data, TEM analysis detected VSG coat on a subset 
(~15%) of the differentiating cells (not shown). 
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3.12.3  Transcriptome analysis of differentiating procyclic cells 
To determine the wider consequences of RBP10 expression in the differentiating 
procyclic cells, I analysed the transcriptome changes of the cells expressing RBP10 
for 24 or 48 hours using RNA-seq; the cells lacking RBP10 served as control. Both 
experiments were done in duplicate (Figure 3.12.3.1). In addition, the transcriptome 
for the newly converted bloodstream form cells was examined to confirm their 
similarity to the wild type EATRO1125 cells; in this case only a single sample from 
each cell line was analyzed.  
The PCA plot on Figure 3.12.3.1 shows the general overview of the RNA-seq data, 
and the reproducibility between the replicates. For the procyclic samples, the control 
clustered separately from the samples where RBP10 was expressed for 24 or 48 
hours; clearly indicating significant differences in the transcriptomes. Interestingly, 
samples from newly converted bloodstream form were closer to wild type 
bloodstream form than to the differentiating cells or the control procyclics cells 
(Figure 3.12.3.1). Their transcriptomes also showed a strong correlation in 
comparison to the rest.  
 
 
Figure 3.12.3.1 PCA plot showing transcriptomes variability. PC=procyclic form; 
BS=bloodstream form; new=newly converted BS; start=parental AnTat1.1 BS with 
an ectopic copy of RBP10.  
 
As reported for the monomorphic cells, expression of RBP10 in procyclic forms 
caused widespread effects on the transcriptome (Figure 3.12.3.2-4). RBP10 
expression for 24 hours led to 357 mRNAs being significantly differentially regulated 
(at least 2x with p<0.05). 242 were up-regulated while 115 mRNAs got down-
regulated. 70% of those up-regulated are more abundant in bloodstream form  
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whereas 61% of those down-regulated are more abundant in the insect stage (Figure 
3.12.3.2-4). The effect got stronger with prolonged expression of RBP10 for 48 hours 
(Figure 3.12.3.2-4). In this case, 1211 transcripts were significantly differentially 
regulated. 760 were up regulated (25% are more abundant in bloodstream form) 
while 451 were down regulated (22% are more abundant in procyclic forms). There 
was a strong positive correlation (R=0.87) between the transcriptome changes after 
24 and 48 hours of RBP10 expression.  
mRNAs encoding procyclic specific membrane proteins were significantly enriched 
within the down regulated transcripts after 24 or 48 hours of RBP10 expression 
(Table 4, Figure 3.12.3.3-4). In agreement with the Western blot result (Figure 
3.12.2.1 A), EP mRNA was more than 5 fold decreased. Other gene classes within 
that list included those involved in the citric acid cycle and mitochondrion respiratory 
pathway (Table 4, Figure 3.12.3.3-4).  
 
 
 
Figure 3.12.3.2 mRNA changes in differentiating procyclic cells. A) A clustered 
heatmap showing the relationship between effects of RBP10 expression and 
developmental regulation. Only mRNAs that were differentially regulated by at least 
2 fold are shown. The developmental regulation data is a ratio of comparison 
between procyclic (PC) versus bloodstream (BS). 
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Figure 3.12.3.3 mRNA changes after RBP10 expression for 24h in procyclic forms. The effect of RBP10 expression on different 
trypanosome gene classes is shown using a box plot. The red line highlight 2 fold cut-off relative to the sample without RBP10. In 
bold are the gene classes found to be significantly over-represented in the subset of mRNAs which were either up or down 
regulated after RBP10 expression for 24h; the pvalue is shown on Table 5. The figure was generated using a custom tool for 
trypanosome transcriptomes, which was designed by Kevin Leiss.  
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Figure 3.12.3.4 mRNA changes after RBP10 expression for 48h in procyclic forms. The analysis was done as in Figure 3.12.3.3.  
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Table 4. Gene class enrichment after RBP10 expression for one or two days. The 
number of the transcripts that met the cut-off (at least 2x, p<0.05) is shown. Gene 
enrichment was determined by Fishers exact test and p-value adjustment using 
Benjamini Hochberg method. The total number of the genes present in the genome 
for each class are shown; --- means the number is indicated in the 24h sample. 
Mito=mitochondrion, e=electron, PAG=procyclin-associated gene, ESAG=expression 
site associated gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Class  
Adjusted  
p value 
No. of 
Genes  
affected  
No. of 
genes in 
the 
genome  Sample 
up-regulated 
 
  
  
  
2
4
h
 +
R
B
P
1
0
 
ESAG 9.67E-05 8 29 
GPI.anchors 9.89E-03 5 17 
Membrane.protein 9.67E-05 9 29 
PAG 6.66E-03 4 7 
Down-regulated 
  
  
  
Citric.acid.cycle 8.28E-05 6 20 
Membrane.protein 3.46E-04 6 --- 
Mito.biogenesis 2.76E-02 4 29 
Mito.e.transport 3.07E-08 14 86 
          
up-regulated 
 
  
  
  
4
8
h
 +
R
B
P
1
0
 
GPI.anchors 0.01 9 --- 
Membrane.protein 0.01 12 --- 
Down-regulated 
 
  
  
--- 
Citric.acid.cycle 1.38E-06 13 --- 
Membrane.protein 1.03E-02 8 --- 
Mito.biogenesis 3.07E-02 7 --- 
Mito.e.transport 2.83E-04 19 86 
Mito.pathway 4.16E-02 29 272 
Nuclear.transport 3.26E-02 9 47 
Nucleotides 2.81E-03 12 51 
Protease 1.23E-02 13 73 
rRNA.tRNA.process 4.40E-04 20 100 
Translation 2.83E-04 18 78 
Translation.tRNA 9.25E-04 10 29 
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The RNA coding for terminal alternative oxidase (TAO) which was used as a 
differentiation marker in the Western blot on Figure 3.12.2.1, increased by two fold 
after 24h of RBP10 expression. RBP10 mRNA was >30x increased (Figure 3.12.3.3-
4), ten other bloodstream form specific transcripts encoding RBPs were also up-
regulated by ~2-5 fold. Consistent with acquisition of bloodstream form morphology, 
the differentiating cells showed increased expression of mRNA coding for membrane 
proteins which are normally abundant in bloodstream forms. For example invariant 
surface glycoprotein ISG65 mRNA was 10x upregulated, major surface protease 
MSP A and C mRNAs were increased by >3x while the procylic form MSP C was 
significantly decreased. Moreover, 5 mRNAs encoding protein required for GPI 
anchor biosynthesis were up regulated as well as 8 ESAG genes (Table 4). 
Surprisingly, mRNAs coding for glycolytic enzyme were mainly up-regulated after 
24h of RBP10 expression but not on day two when bloodstream form cells were 
detected (Figure 3.12.3.3-4); possibly due to growth defect seen on day two (Figure 
3.12.2.1 A). mRNAs encoding proteins involved in translation appeared not to be 
significantly affected after 24 hours of RBP10 expression, however longer 
expression for two days clearly affected translation with mRNAs encoding different 
factors needed for general translation being enriched in the down regulated set of 
mRNAs (Figure 3.12.3.3-4, Table 4). Others that were down regulated and enriched 
only in the 48 hours dataset included chaperone, protease, nuclear transport and 
nucleotides gene classes (Table 4). 
Despite only 16% of the cells having morphological signatures of bloodstream form 
cells after 48 hours of RBP10 expression, the transcriptome points out an on going 
procyclic to bloodstream differentiation process. Comparison between the 
transcriptomes of the differentiating cells and the transcriptomes of the 
trypanosomes found in the tsetse fly showed a weak positive correlation to those 
parasites found in the proventriculus as they differentiate towards the salivary gland. 
BARP mRNA which is strongly up regulated (12x) in one such life stage 
(epimastigote) was ~2 fold up regulated after RBP10 expression for 2 days, however 
BARP protein was not detected by Western blotting. This suggests that RBP10 
meditated conversion does not follow the classical life cycle progression seen in the 
fly, rather the differentiating cells may be jumping straight to the metacyclic forms. 
Alternatively the cells could be differentiating backwards from procyclic to 
bloodstream forms.  
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3.12.4  Metacyclic VSGs identification 
To find out whether the procyclic cells were going forward in the life cycle or 
switching backwards, I looked for the VSG transcripts expressed in the metacyclic 
forms. One of the unique features of metacyclic trypanosomes is the monocistronic 
transcription of their VSGs. The promoter driving the metacyclic VSG expression is 
located ~3 kb upstream of the active VSG, this is in contrast to the normal 
bloodstream forms where the promoter is ~ 60 kb upstream of the active VSG gene; 
normally separated by ESAG genes. To find out whether there were metacyclic 
VSGs expressed in the cell populations, I did a de novo assembly of the 
transcriptomes shown in Figure 3.12.3.1. The obtained contigs were then searched 
for a conserved motif present in the 3’ UTR of all VSG mRNAs. 47 contigs ranging 
709-4788 bp were found. Majority of them (41 out of the 47) were identified from 
procyclic cells expressing RBP10, the other six contigs were from the newly 
converted bloodstream and the starting bloodstream forms cultures. Consistent with 
the RT-PCR (Figure 3.12.2.1) result, no contigs containing the conserved VSG motif 
were found in uninduced procyclic cells. To determine whether the contigs from the 
48h RBP10 cultures contained partial or full length VSG CDS, the sequences were 
subjected to a BLASTn analysis against the T. brucei genome at NCBI. The results 
were comparable between the replicates with multiple contigs having the same VSG 
hit. Out of the 47 contigs, 20 unique VSG hits were present; among the unique set 
50% had complete VSG CDS while 45% had a near complete VSG (78-98% 
identical) CDS (Table 5). Interestingly, the metacyclic VSG MVSG5 [160] was 
present among the eight unique contigs obtained from procyclic cells expressing 
RBP10 for 24h or 48h (Table 5). To estimate the transcript levels for the unique set 
of VSGs, I re-analysed the transcriptome data and included the CDS sequences 
from the 20 VSGs (Table 5). The starting bloodstream form cells mainly expressed 
AnTat1.1 VSG transcript which accounted for ~5% of the total mRNA (Table 5). On 
the contrary, procyclic cells expressing RBP10 for two days showed >100x 
increased expression of eight different VSG transcripts (Table 5 highlighted in blue); 
which as well accounted for 4-5% of the total mRNA. Out of eight, only MVSG5 
expression site was previously known to be present in the ETRO1125 genome [161], 
the other seven might be novel metacyclic VSGs.  
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To find out whether the other seven VSGs are putative metacyclic VSGs I looked for 
the presence of the metacyclic promoter. This was not possible using the 
transriptome assembly data because the promoter is not present in the primary 
transcript. Therefore, I assembled shotgun reads from the EATRO1125 genome 
(~30x coverage [148]). 18 contigs with at least 4 kb (the longest was ~17 kb) 
included sequence with resemblance to VSG mRNAs. 3 out of the 18 were detected 
after RBP10 expression in procyclic cells and had a complete VSG CDS (Table 5 
highlighted in light green). Interestingly, in all three contigs a metacyclic promoter 
was present on the sequence upstream of the CDS. Multiple sequence alignment 
showed a high conservation with known metacyclic promoter sequences (Figure 
3.12.4). A putative ESAG1 could be identified in two of the contigs. One sequence 
(~7.4 kb) was 99.4% identical to the previously reported metacyclic MVSG5 
expression site [160, 161]; the other (~17 kb) had a putative ESAG9, and showed 
resemblance to ILTat 1.22 metacyclic expression site [162] but with a different VSG 
CDS.  
Therefore, RBP10 expression for 2 days causes the procyclic cells to switch towards 
the metacyclic state. 
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Table 5 The raw read counts for 20 unique VSG CDS identified from the transcriptomes of EATRO1125 and procyclic cells 
expressing RBP10. Highlighted in light green are the three putative metacyclic VSGs. The eight VSGs detected after RBP10 
expression are shown in blue. The RPMs of total VSG counts estimated based on the total RNA is shown.     
 Nearest 
VSG 
Accession 
No. 
CDS_
size 
(NCBI
) 
CDS %  
identity 
BS  
new 
BS  
start 
24h 
PC  
(A) 
24h 
PC  
(B) 
48h 
PC 
(A) 
48h 
PC 
(B) 
ctrl  
PC 
(A) 
ctrl  
PC 
(B) 
Metacyclic 
promoter? 
KX700731.1 
(AnTat1.1) 
1521 89 38 1530446 2 5 737 280 4 46 na 
KX699100.1 1527 100 333 559434 51 79 3898 1270 5 25 na 
KX701110.1 1329 100 763 536 33780 126840 2011130 965390 266 125 yes 
KX701187.1 1266 100 84 56 2200 7146 183965 105932 54 11 na 
KX699860.1 1551 100 52 22 3389 11911 89263 38447 136 34 na 
KX699226.1 1431 100 9 6 1042 3469 45387 17981 52 25 yes 
AF259553.1 
(MVSG5) 
1554 100 9 6 709 2324 45237 31741 53 10 yes 
KX698697.1 1473 100 145 83 99 132 13327 2820 3 1 na 
KX699246.1 1392 100 164 116 88 134 12814 2763 3 2 na 
KX700057.1 1428 78 1 4 211 916 10622 5951 5 3 na 
KX700095.1 1512 87 51 10 19 54 3149 1029 2 0 na 
KX699008.1 1605 98 144 14 14 22 1433 402 0 0 na 
KX699224.1 1434 92 24 27 330 1016 792 300 192 116 na 
KX699312.1 1350 100 231 193 33 100 714 250 3 1 na 
KX700970.1 1416 87 50 21 3 4 502 75 2 0 na 
KX698690.1 1488 100 107 55 14 9 435 20 2 0 na 
KX700619.1 1620 95 37 523 3 4 116 46 3 0 na 
KX699109.1 1518 83 653170 32 2 517 60 19 1 1 na 
KX698657.1 1521 47 189 17 0 1 1 2 0 0 na 
  Total 655601 2091601 41989 154683 2423582 1174718 786 400  
  RPM 19565 75401 1582 1943 42683 51171 21 14  
  %VSG 1.96 7.54 0.16 0.19 4.27 5.12 0.00 0.00  
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Figure 3.12.4 Multiple sequence alignment of the identified promoters. A) Sequence conservation with known metacyclic 
promoters for IlTat1.63, ILTat1.22 and MVSG5 metacyclic VSGs. B) A phylogenetic tree showing distances of the alignment.       
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4 Discussion 
Previous study showed RB10 is a cytoplasmic RNA binding protein that is essential 
in bloodstream form trypanosome [91]. RBP10 expression is tightly regulated during 
life cycle transitions. In the stumpy and the insect stage procyclic forms RBP10 
protein is undetectable [91, 105, 131], RBP10 mRNA is however up regulated in the 
life stage forms present in the salivary gland of the tsetse fly [163]. Alteration of 
RBP10 expression by RNAi in bloodstream form or over expression in procyclics 
cells caused profound transcriptome changes [91] mimicking early differentiation 
events between the two life stages. During my PhD, I investigated how RBP10 acting 
as a repressor mediates such changes. In addition, the role of RBP10 in 
differentiation commitment was examined. 
 
4.1 RBP10 is a repressor protein 
When the C-terminus of RBP10 is attached to a reporter mRNA, the mRNA is 
removed from actively translating polyribosomes resulting to mRNA degradation and 
translation repression. We speculated RBP10 acts by associating with the mRNA 
degradation machinery, however, we obtained no convincing evidence for this 
hypothesis. Yeast two hybrid screening and TAP purification using RBP10 failed to 
identify such a link. The only possible candidate from RBP10 TAP was CAF40, but 
RBP10 was not detected in the mass spec analysis after V5-CAF40 pull-down. 
Alternatively, the degradation machinery may be recruited indirectly via RBPs 
associating with RBP10. Interesting candidates found by yeast two hybrid included 
DRBD11, DRBD7, ZC3H13, ZC3H15, and three hypothetical proteins 
(Tb927.11.14220, Tb927.6.5010, Tb927.8.910). All were unique to RBP10 two 
hybrid screen, and they act as repressor of gene expression when tethered to a 
reporter mRNA. Six of the interacting partners bind to mRNAs in bloodstream form 
[82] and in case of ZC3H15, interaction with deadenylase CAF1 in a yeast two hybrid 
has been reported [82].  
For the non RBPs, 4E-IP, a major repressor protein when tethered, [82, 83] was also 
present. Convincingly, the 4E-IP yeast two hybrid screen identified RBP10 as one of 
its interacting partners. The interaction between 4E-IP and RBP10 was confirmed in 
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trypanosomes as well, and only a very small proportion of the proteins associated 
with each other. Knock out of 4E-IP is however possible in bloodstream forms 
(unpublished result from our lab) which suggests that it is not a key contributor to the 
biological function of RBP10 in bloodstream forms. Follow up studies on the 
identified putative partners of RBP10 will help to understand its mechanism of action. 
 
The repressive C-terminal (88 residues) fragment of RBP10 is rich in polar (31%) 
and hydrophobic (34%) amino acids. Deletion of this region prevents aggregation of 
RBP10 in vitro (Bin Liu and Igor Minia, unpublished). So far there is no evidence 
showing aggregation of RBP10 in bloodstream form trypanosomes where it is 
normally expressed. However, ectopic expression of eYFP tagged RBP10 in 
procyclic forms [164] showed RBP10 colocalize with processing body (P-body) 
markers DHH1 and SCD6, which further support the hypothesis that RBP10 acts as 
a repressor of gene expression. In mammalian cells and yeast, P-bodies contain 
proteins involved in mRNA degradation and translation repression as well as the 
silenced mRNAs [67].  
 
4.2 RBP10 affects developmental regulation of many mRNAs bound by it  
Regulation of trypanosome gene expression is important especially during life cycle 
transitions. One well studied differentiation step is from bloodstream to procyclic 
form. Evidence from transcriptome and proteome analyses during differentiation 
[105, 131, 165] point out a well coordinated series of events including change of the 
surface coat proteins, mitochondrion activation and switching of the energy 
metabolism from glycolysis to oxidative phosphorylation. Transcripts encoding 
proteins involved in these pathways are normally repressed in long slender 
bloodstream form. We speculated the negative regulation in bloodstream form is 
facilitated by RBP10. This is strongly supported by several facts: first, RBP10 acts as 
a repressor when tethered to mRNA. Second, RBP10 is strongly down regulated 
during differentiation and is absent in procyclic forms. Third, RNAi targeting RBP10 
in bloodstream form mimic changes seen early during differentiation to procyclic 
forms; such as increase in expression of mRNAs encoding procyclic surface coat EP 
procyclin, regulatory proteins ZC3H22, ZC3H20 and several proteins involved in 
different mitochondrion specific pathways. Lastly, RBP10 co-purifies many mRNAs 
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that are normally up regulated in the procyclic forms and/or show increased 
expression during differentiation; this includes more than one third of the transcripts 
up-regulated after RBP10 RNAi.   
The motif UA(U)6 found to be enriched in the 3’ UTRs of transcripts bound by RBP10 
is present in a wide selection of procyclic specific mRNAs. It was suggested more 
than ten years ago that the U-rich motif could be required for widespread 
developmental regulation of procyclic specific mRNAs [166]; similar to the 
destabilising AU-rich elements found in many mammalian mRNAs. In T. brucei 
bloodstream forms, the U-rich motif is already implicated in the negative regulation of 
mRNAs encoding EP procyclin [155], the B isoform of phoshoglycerate kinase [167], 
pyruvate phosphate dikinase [167] and cytochrome oxidase subunit COX V [166]. 
This is the first study to identify a bloodstream form trans acting factor that binds the 
motif and negatively regulates a significant number of procyclic specific mRNAs 
including some of those previously studied. Hence, RBP10 is a key regulator which 
is required for the maintenance of the bloodstream form life stage. We suggest it 
acts by recognizing the UA(U)6 motif present in many procyclic specific mRNAs 
targeting them for translation repression and mRNA degradation.  
 
In other eukaryotes, the deadenylation complex CCR4-CAF1-NOT triggers mRNA 
degradation; this is directed by RNA binding proteins (RBPs) which interact with the 
mRNA degradation machinery. For example yeast Mpt5p (RBP of the PUF family) 
recruits Pop2p (CAF1), the RNA helicase Dhh1p and decapping activator Dcp1 to 
heme oxygenase (HO) transcripts, which promote HO mRNA degradation [168]. The 
zinc finger protein tristetrapolin (TTP) mediates degradation of many AU-rich 
element (ARE) containing mRNA in mammalian cells by interacting with different 
enzymes involved in mRNA degradation pathways [169]. 
The mode of action of RBP10 appears not to involve the recruitment of the CAF1-
NOT complex since tandem affinity purification using TAP tagged RBP10 failed to 
co-purify the machinery involved in mRNA degradation. However, the interaction with 
RBP10 may be transient hence not detectable using the TAP approach. This can be 
improved by adding an in vivo cross-linking step to freeze both weak and transient 
interactions taking place in intact cells before lysis.  
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Not all mRNAs that changed in abundance after RBP10 RNAi were bound by 
RBP10. This could be as a result of indirect effects from other regulatory proteins; 
the up regulated RBPs include ZC3H22 and ZC3H20. ZC3H22 is essential in 
procyclic forms [105] and acts as a negative regulator [82] when tethered to a 
reporter mRNA. Increased ZC3H22 expression therefore will result in a decrease in 
its target mRNAs. ZC3H20 is more abundant in procyclic forms where it is known to 
bind and stabilize two mRNAs [96]. Interestingly, one of ZC3H20 targets increased 
after RBP10 RNAi and was not bound by RBP10; this could be due to the increased 
levels of ZC3H20 after RBP10 RNAi. 
For the transcripts that were bound by RBP10 but did not increase after RBP10 
RNAi, we speculate other proteins dominate the regulation. Trypanosome mRNAs 
have a median 3’UTR length of 300nt. There is therefore space to bind multiple RNA 
binding proteins (RBPs), which can further interact with other proteins. As a result, 
the fate of the mRNA is determined by the ensemble of all associated RBPs.  
 
RBP10 contain a single RRM domain, which probably is not sufficient to bind the 
eight nucleotide long UAUUUUUU motif present in many of its target mRNAs. The 
RRM is a sequence of about 90 amino acids, and consists of a four-stranded 
antiparallel β-sheet packed against two α-helices [170]; this forms a platform that 
predominantly binds single-stranded RNA. Each RRM domain can bind 4-6 
nucleotides [171]. In the well studied mammalian RRM containing proteins, the 
presence of more than one RRM domain confers increased affinity and sequence 
specificity [172]. I have showed RBP10 self-interact in a yeast two hybrid assay, it is 
conceivable that RBP10 dimerizes as a homodimer; this possibly improves binding 
specificity of RBP10 since it has a single RRM domain. Furthermore, the presence of 
multiple copies of the motif within a single transcript raises the probability of binding 
and could allow more than two RBP10 to bind.  
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4.3 Role of RBP10 in differentiation commitment  
A PTP1/PIP39 phosphatase cascade [152] controls the differentiation from 
bloodstream to procyclic forms via an intermediate stage known as the stumpy form. 
Up regulation of phosphorylated PIP39 and its relocation to the glycosome is 
required for the differentiation; this is promoted by temperature reduction plus 
incubation with the differentiation trigger cis-aconitate.  
The PTP1 and PIP39 mRNAs were neither bound by RBP10 nor affected by 
depletion of RBP10 in bloodstream forms. However, the PIP39 protein level was 
strongly increased after RBP10 RNAi; which is a key signature for cells 
differentiating to procyclic forms. This finding plus the fact that alteration of RBP10 
expression in procyclic forms causes reverse developmental regulation of many 
mRNAs led us to speculate a biological function in differentiation commitment. 
Indeed, pleomorphic bloodstream forms cells depleted of RBP10 differentiated to 
procyclic forms after transfer into procyclic growth media and incubation at 27oC. 
Therefore, depletion of RBP10 primes bloodstream form cells to differentiate to 
procyclic forms in absence of differentiation trigger cis-aconitate. This could be as a 
result of metabolic changes after RBP10 RNAi that triggers downstream signaling 
pathways involved in differentiation; one example is increased expression of PIP39 
protein. Other regulatory factors implicated in bloodstream to procyclic form 
differentiation include two transcripts encoding protein kinases, RDK1 and NRKA, 
that were bound but not regulated by RBP10. Similar to PIP39, their protein levels 
might have changed as part of a regulatory cascade caused by the loss of RBP10. 
RDK1 is essential in bloodstream form [122] hence it should not be regulated by 
RBP10 that acts as a repressor. NRKA [105] is up regulated after the onset of the 
stumpy form differentiation. Similar to RBP10, depletion of RDK1 primes 
bloodstream forms to differentiate to procyclic forms [122]. More than 20 mRNAs 
show similar changes after depletion of either RDK1 or RBP10, 16 of these are both 
bound and regulated by RBP10. Surprisingly, RBP10 transcript was not affected 
after RDK1 RNAi, however, the protein level and phosphorylation status of RBP10 
were not determined. 
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The connection between differentiation signaling pathways and trypanosome gene 
expression is not well known. In the absence of transcription initiation control in T. 
brucei, RBP10 could be one of the effector molecules targeted by the differentiation 
signaling pathways. Understanding how RBP10 is regulated is the next major 
question. Regulation could be at the level of mRNA or protein. The very long (~7.5 
kb) 3' UTR of RBP10 possibly harbours multiple regulatory elements as well as 
secondary structures. Recruitment of different mRNP complexes via such elements 
could influence stability and/or translation of RBP10 mRNA in a life stage specific 
manner; it won't be surprising that RBP10 3' UTR acts as a sensor during 
differentiation. On going studies (being done by Larissa Melo Do Nascimento) aim to 
map the elements required for the negative regulation of RBP10 mRNA in procyclic 
forms. The long-term goal is to identify the responsible trans acting factors. In terms 
of protein, RBP10 is known to be phosphorylated (four sites) in bloodstream forms 
[173]; the kinase involved is not known. Also, it remains to be determined whether 
those modifications regulate the biological function of RBP10. This could be tested 
using conditional knock out in the presence of either wild type RBP10 or mutants 
lacking the phosphorylation sites. 
 
The conversion from procyclic form back to the mammalian infective metacyclic 
forms occurs naturally in the tsetse fly. It involves complex life cycle transitions with 
more than five different life stage forms being generated [37]; most of these life 
stages cannot be cultured in vitro. Strikingly, over expression of RBP10 in 
EATRO1125 derived procyclic cells for two days converted a subset of the cells to 
bloodstream forms. As expected, mRNAs enriched in the procyclic forms were 
strongly down regulated after RBP10 expression; including most of RBP10 mRNA 
targets. Secondary effects cannot be ruled out since growth was also affected. The 
transcriptome of the differentiating cells showed a weak positive correlation to the 
transcriptome of the parasites found in the tsetse fly, specifically those migrating 
from the proventriculus towards the salivary gland. One epimastigote stage marker 
BARP [42] which is twelve fold up regulated (at the mRNA level) relative to the 
procyclic forms [163] was only increased by about two fold after RBP10 expression. 
BARP protein was undetectable as were cells with epimastigote morphology; 
perhaps they constituted less than one percent of the cell population making it hard 
to find them. This is in contrast to what was observed in case of over expression of 
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RNA binding protein RBP6 [92]; where RBP6 promoted in vitro generation of 
epimastigotes within a day and mature infective metacyclic forms in five days [92]. It 
is likely that RBP10 mediated conversion jumps straight to the metacyclic forms 
hence does not follow the natural life cycle. This is supported by the detection of the 
transcripts encoding metacyclic VSGs in the differentiating cells expressing RBP10 
for 24 and 48 hours. Interestingly, depletion of RBP10 in procyclic cells over 
expressing RBP6 leads to epimastigote cells but generation of metacyclic forms is 
blocked (unpublished result from C. Tschudi lab). This demonstrates that RBP10 is 
downstream of RBP6, and helps to define the long slender bloodstream form life 
stage.  
When RBP10 is absent in bloodstream forms, the cells can only survive as procyclic 
forms. Conversely, expression of RBP10 in procyclic forms converts some of the 
cells to bloodstream form. We suggest RBP10 acts as a regulatory switch controlling 
Trypanosoma brucei differentiation.  
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